

**CURRICULUM VITAE
SHAKER R. DAKHIL, M.D., F.A.C.P.**

Office Address: 818 N. Emporia, #403, Wichita, KS 67214
Office Phone: (316) 262-4467

Present Position: President, Cancer Center of Kansas, P.A.
818 N. Emporia #403
Wichita, Kansas 67214
(316) 262-4467

Date of Hire: **July 1, 1981**

EDUCATION:

Undergraduate	Lycee Franco Libanais, Beirut, Lebanon Mathematiques degree	1968
Graduate	St. Joseph University School of Medicine, Beirut, Lebanon M.D. degree	1968-75
Postgraduate	Wayne State University, Detroit, MI Resident in Internal Medicine	1975-78
	University of Michigan School of Medicine, Ann Arbor, MI Fellow, Oncology/Hematology	1978-81

PROFESSIONAL CERTIFICATION:

American Board of Internal Medicine	9/78-Current
Oncology	1982-Current
Hematology	1982-Current

ACADEMIC APPOINTMENTS:

The University of Kansas School of Medicine - Wichita, Wichita, KS Department of Internal Medicine	
Clinical Assistant Professor	8/81-90
Associate Professor	7/90-92
Clinical Associate Professor	7/92-01
Clinical Professor of Medicine	7/01

HOSPITAL APPOINTMENTS:

Via Christi Regional Medical Center, Wichita, KS St. Francis campus:	
Institutional Review Board	1985-90
St. Joseph campus:	
Cancer Committee	1981-
Utilization Review Committee	1984-90
Institutional Review Board Chairman	1985- 1985-86, 1989, 1990-91
Transfusion Committee, Chairman	1990-91
Columbia Wesley Medical Center	
Cancer Committee	1987-
IRB Committee	1990-
Via Christi Medical Center	
Medical Staff President-elect	1998
Medical Staff President	1999

MEDICAL LICENSURE:

Kansas, FLEX, active

MEDICAL SOCIETY MEMBERSHIPS:

Medical Society of Sedgwick County	1981-
Insurance Committee	1992-94
Treasurer	1992
Vice-President elect	1994
President-elect	1996
President	1997-1998
Kansas Medical Society	1981-Current
American Medical Society	1981-Current

PROFESSIONAL ORGANIZATIONS:

American College of Physicians	
Fellow	1987-Current
ASCO	Current
American Society of Hematology	Current
American Society of Internal Medicine	Current
Kansas Society of Clinical Oncology	
President	2001-2004

ADMINISTRATIVE APPOINTMENTS:

Cancer Research of Kansas	2019-Current
Principal Investigator	
Ascension Via Christi Oncology Services	2000-
Medical Director	
Wichita Community Clinical Oncology Program	2000-2019
Principal Investigator	
Wichita Community Clinical Oncology Program	1983-2000
Investigator	
Southwest Oncology Group	1983- Current
GI Committee	
Blue Cross and Blue Shield of Kansas	
Liaison Committee	1989- Current
National Surgical Adjuvant Breast & Bowel Project	
Co-principal investigator	1996-2000

HONORS:

Graduated first in medical school class of '68	1975
Harry Hynes Award for Excellent Leadership in Community Clinical Oncology Program Research by National Cancer Institute	2002
National Cancer Institute (NCI)	2002
Recipient of the first Harry Hynes Award for Excellence in Community Clinical Oncology Research	
Special Recognition Award for Exceptional Service in Clinical Trials by National Cancer Institute	2005

US News & World Report	
Named to Top 1% of Physicians for Oncology in the Nation by Castle Connolly Medical Ltd.	2005-2017
Recognized as America's Top Doctors	2009-2016
Platinum Award for ≥ 25 Patients in Total Accruals in WCCOP NCI/Cancer Control Clinical Trials (3 rd highest enrollment of patients in WCCOP NCI/Cancer Control Clinical Trials)	2011
Selected as one of two <i>Wichita Business Journal's</i> Health Care Heroes for Lifetime Achievement	2014
Recipient of <i>Wichita Business Journal</i> Innovations Award	2016
Kansas Humanitarian of the Year Award from the Kansas Humanitarian Commission	2016
ExpertScape	
Named to Top 0.097% of Combination Drug Therapy Experts	2019
Chosen Best in Oncology Medicine, Physicians Category, in Cowley County	2019

COMMUNITY SERVICE:

American Cancer Society	1989-90
Board of Directors	1988-

BIBLIOGRAPHY

Scientific papers submitted but not yet accepted:

1. Palesh O, Mustain K, Heckler C, Purnell J, Peppone L, Weiss M, Atkins JN, Dakhil SR, Spiegel D, Morrow G. A Phase III Randomized Prospective Trial Of The Effect Of Psychotherapy On Distress In 287 Prostate Cancer Patients: a URCC CCOP Study (U9994). (submitted to ASCO as abstract 1/09)
2. Ryan JL, Heckler C, Dakhil SR, Kirshner J, Flynn PJ, Hickok JT, Morrow GR. Ginger For Chemotherapy-Related Nausea In Cancer Patients: a URCC CCOP Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of 644 Cancer Patients. (submitted to ASCO as abstract 1/09).
3. Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhil SR. Phase II Evaluation Of Gefitinib In Patients with Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group study N0074.
4. Kim GP, Foster NR, Oberg AL, Jaslowski AJ, Alberts SR, Flynn PJ, Dakhil SR, Mowat RB, Garneau SC. NCCTG Phase II Trial Of Bevacizumab, Gemcitabine, Oxaliplatin In Patients with Metastatic Pancreatic Adenocarcinoma, N034A. Submitted to Cancer June 2009.
5. Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson D, Mattar BI, Moore DF, Nikcevich D, Loprinzi CL. A Randomized Comparison of Standard Weekly Epoetin Alfa To Every 3-Week Epoetin Alfa and Every 3-Week Darbepoetin Alfa: a Study of The Mayo Clinic Cancer Research Consortium (MCCRC). Submitted to ASH as abstract July 2009.
6. Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM, Schaefer PL, Novotny PJ, Wender DB, Gross HM, Loprinzi CL. Tetracycline For Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rash: Results Of a Placebo-Controlled Trial From The North Central Cancer Treatment Group (N03CB).
7. Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton P, Rowland KM, Bearden JD, Johnson DJ, Bernath AM, Soori GS, Flynn PJ, Loprinzi CL. Long Acting Methylphenidate For Cancer-Related Fatigue: a Phase III, Randomized, Double-Blind Placebo Controlled Study, NCCTG Trial N05C7. (January 2010).

Scientific papers with single or multiple authors (peer reviewed):

1. Dakhil S, Ensminger W, Kindt G, Niederhuber J, Chandler W, Greenberg H, Wheeler R. An Implanted System For Intraventricular Drug Infusion In CNS Tumors. *Cancer Treat Rep.* 1981; 65 (5-6): 401-411.
2. Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R. A Totally Implanted Drug Delivery System For Hepatic Arterial Chemotherapy. *Cancer Treat Rep.* 1981 June; 65 (5-6): 393-400.
3. Greenburg HS, Ensminger WD, Seeger JF, Kindt GW, Chabdker F, Doan K, Dakhil SR. Intra-Arterial BCNU Chemotherapy For The Treatment Of Malignant Gliomas Of The Central Nervous System: a Preliminary Report. *Cancer Treat Rep.* 1981 (9-10): 803-810.
4. Gyves J, Ensminger W, Niederhuber J, Liepman M, Cozzi E, Doan K, Dakhil S, Wheeler R. Totally Implanted System For Intravenous Chemotherapy In Patients with Cancer. *Am J Med.* 1982; 73 (6): 841-845.
5. Dakhil S, Ensminger W, Cho K, Niederhuber J, Doan K, Wheeler R. An Improved Regional Selectivity Of Hepatic Arterial BCNU with Degradable Microspheres. *Cancer.* 1982; 50: 631-635.
6. Housholder DF, Hynes HE, Dakhil SR, Marymont JV. Hepatobiliary scintigraphy in patients receiving hepatic artery infusion chemotherapy. *J Nucl Med.* 1985 May 26:474-477.
7. Marymont JV, Dakhil SR, Travers H, Housholder DF. Chemical Cholecystitis Associated with Hepatic Arterial Chemotherapy Delivered By a Permanently Implanted Pump. *Hum Pathol.* 1985 Oct 16: 986-990.
8. Ernst R, Chang F, Hynes HE, Dakhil SR, Farha GJ. An Implantable Drug Delivery System. *Kans Med.* July 1986:198-200.
9. Grever MR, Benedetti J, Balcerzak SP, Taylor SA, Miller TP, Dakhil SR. A Southwest Oncology Group Phase II Evaluation Of Fludarabine Monophosphate In Sarcoma. *Invest New Drugs.* 1994;12:259-261.
10. Shin DM, Holoye PY, Forman A, Winn R, Perez-Soler R, Dakhil S, Rosenthal J, Robert MN, Hong WK. Phase II Clinical Trial Of Didemnin-B In Previously Treated Small Cell Lung Cancer. *Invest New Drugs.* 1994;12: 243-249.
11. Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin G: Phase II Evaluation Of Fluorouracil And Recombinant Alpha-2a-Interferon In Previously Untreated Patients with Pancreatic Adenocarcinoma. *Cancer.* 1992 Oct 15; 70 (80): 2073-2076.
12. Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, Loyer E, Rusinkiewicz J, Gacrama P, Fueger R, Kavanaugh J: Activity of Paclitaxel in Advanced or Recurrent Squamous Cell Cancer of the Cervix. *Clin Cancer Res.* 1996;2:1285-1288.
13. Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, LoCoco S, Umbreit J, Delmore JE, Arbuck S, Loyer E, Gacrama P, Fueger R, Kavanagh JJ: An Update Of a Phase II Study Of Paclitaxel In Advanced Or Recurrent Squamous Cell Cancer Of The Cervix. *Anti-Cancer Drugs.* 8: 657-661.
14. Samer E. Kaba, Athanassios P. Kyritsis, Kenneth Hess, W.K. Alfred Yung, Richard Mercier, Shaker Dakhil, Kurt A. Jaeckle, and Victor A. Levin: TPDC-FuHu Chemotherapy for the Treatment of Recurrent Metastatic Brain Tumors. *J Clin Onc.* 1997 March 15;3:1063-1070.
15. Pandya KJ, Flynn PJ, Dakhil SR, Rosenbluth RJ, Kirshner JJ, Pierce HI, Raubertas RF: Oral Clonidine in Postmenopausal Breast Cancer Patients with Tamoxifen-Induced Hot Flashes. a URCC CCOP Study.
16. Pazdur R, Medgyesy DC, Winn RJ, Dakhil SR, Moore Jr. DF, Scalzo A, Hoff PM, Arbuck SG, Abbruzzese JL: Phase II Trial Of 9-Aminocamptothecin (NSC 603071) Administered As a 120- Hour Continuous Infusion Weekly For Three Weeks In Metastatic Colorectal Carcinoma. *Invest New Drugs.* 1999; 16: 341-346.
17. Taylor SA, Girouz DJ, Jaeckle KA, Panella TJ, Dakhil SR, Schold SC: Phase II Study of Didemnin B in Central Nervous System Tumors. a Southwest Oncology Group Study. *Invest New Drugs.* 1999; 16: 331-332.
18. Holcombe RF, Jacobson J, Dakhil SR, Stewart RM, Betzing KS, Kannan K, Macdonald JS: Association Of Immune Parameters with Clinical Outcome In Stage III Colon Cancer: Results Of Southwest Oncology Group Protocol 9009. *Cancer Immunol Immunother.* 1999; 48: 533-539.

19. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ: Venlafaxine In Management Of Hot Flashes In Survivors Of Breast Cancer: a Randomized Controlled Trial. *Lancet*. 2000; 356: 2054-2063.
20. Pienta KJ, Fisher EI, Eisenberger MA, Mills GM, Goodwin JW, Jones JA, Dakhil SR, Crawford DE, Hussain M: A Phase II Trial of Estramustine and Etoposide in Hormone Refractory Prostate Cancer: a Southwest Oncology Group Trial (SWOG 9407). *The Prostate*. 2001; 46: 257-261.
21. List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D, Dakhil SR, Appelbaum FR: Cyclosporine Inhibition of P-Glycoprotein in Chronic Myeloid Leukemia Blast Phase. *Blood*. 2002; 100: 5: 1910-1912.
22. Klein CE, Tangen CM, Braun TJ, Hussain MHA, Peereboom DM, Nichols CR, Rivkin SE, Dakhil SR, Crawford ED: Evaluation of Topotecan in Hormone Refractory Prostate Cancer: a Southwest Oncology Group Study (SWOG-9510). *The Prostate*. 2002; 52: 262-268.
23. Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode LM, Dakhil SR, Crawford ED: Phase II Trial of Recombinant Human Interleukin-4 in Patients with Advanced Renal Cell Carcinoma: a Southwest Oncology Group Study. *J Immunother*. 2002; 25(4):352-358.
24. Alberts SR, Townley PM, Goldberg RM, Cha SS, Sargent DJ, Dakhil SR, Krook FE, Buckner JC, Fitch TR, Wiesenfeld M, Mailliard JA: Gemcitabine and Oxaliplatin for Patients with Advanced or Metastatic Pancreatic Cancer: a North Central Cancer Treatment Group (NCCTG) Phase I Study. *Annals of Oncology*. 2002; 13:553-557.
25. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B: Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia. a North Central Cancer Treatment Group Study (NCCTG). *J Clin Onc*. 2002; 20(2):567-573.
26. Velasquez WS, Lew D, Grogan TM, Spiridonidis CH, Balcerzak SP, Dakhil SR, Miller TP, Lanier K, Chapman RA, Fisher RI: Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501. *J Clin Onc*. 2003; 21(10):1996-2003.
27. Hickok JT, Roscoe JA, Morrow GR, Bushunow P, Shelke AR, Matteson S, Dakhil SR, Flynn PJ: Occurrence of Severe Nausea in 194 Women Treated with Doxorubicin for Breast Cancer. *Supp Care in Can*. 2003; 11:393-394.
28. Jatoi A, Ellison NM, Burch PA, Sloan JA, Dakhil SR, Novotny PJ, Tan WW, Fitch TR, Rowland KM, Young CYF, Flynn PJ: A Phase II Trial of Green Tea in the Treatment of Androgen-Independent Metastatic Prostate Cancer. *Cancer*. 2003; 97:1442-1446.
29. Velasquez WS, Lew D, Grogan TM, Spiridonidis CH, Balcerzak SP, Dakhil SR, Miller TP, Lanier KS, Chapman RA, Fisher, RI: Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma. *J Clin Onc*. 2003;21(10):1996-2003.
30. Shields CG, Morrow GR, Griggs J, Mallinger J, Roscoe J, Wade JL, Dakhil SR, Fitch TR. Decision-making role preferences of patients receiving adjuvant cancer treatment: a university of Rochester cancer center community clinical oncology program. *Support Cancer Ther*. 2004 Jan 1;1(2):119-26. doi: 10.3816/SCT.2004.n.005. PubMed PMID: 18628188.
31. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS: Effect Of Doxorubicin Plus Cyclophosphamide On Left Ventricular Ejection Fraction In Patients with Breast Cancer In The North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. *J Clin Path*. 2004; 22(18):3700-3704.
32. Le QT, McCoy J, Williamson S, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides DS, Crowley JJ, Gandara DR: Phase I Study Of Tirapazamine Plus Cisplatin/Etoposide And Concurrent Thoracic Radiotherapy In Limited-Stage Small Cell Lung Cancer (S0004): a Southwest Oncology Group Study. *Clin Can Res*. 2004;10:5418-5424.
33. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan M, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR: Randomized Phase II Study Of Two Irinotecan Schedules For Patients with Metastatic Breast Cancer Refractory To An Anthracycline, a Taxane Or Both. *J Clin Onc*. 2004;22(14):2849-2855.

34. Jatoi A, Rowland KM, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Mailliard JA, Bushey TI, Nair S, Christensen BJ: An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both For Patients with Cancer-Associated Wasting. a NCCTG Study And NCI Of Canada Collaborative Effort. *J Clin Onc.* 2004;22:2469-2476.
35. Jatoi A, Egner JR, Loprinzi CL, Sloan JA, Novotny PJ, Dakhil SR, Mailliard JA, Klee FF, Krook JE: Investigating the Utility of Serum Cytokine Measurements in a Multi-Institutional Cancer Anorexia/Weight Loss Trial. *Supp Care in Can.* 2004; 12:640-644.
36. Gotay CC, Moinpour CM, Jiang CS, Ankerst DP, Coleman D, Martino S, Taylor B, Bearden J, Dakhil S, Gross H, Albain DS: Enhancing Well-Being During Breast Cancer Recurrence: Preliminary Finding From a Phase III Study. *Br Can Res Treatment.* 2004;88(Suppl 1):S140(#3080).
37. Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR: Phase II Trial Of Dolastatin-10 In Patients with Advanced Breast Cancer. *Invest New Drugs.* 2005; 23:257-261.
38. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufman S: A Phase II Trial Of Single-Agent Temsirolimus (CCI-779) For Relapsed Mantle Cell Lymphoma. *J Clin Onc.* 2005; 23(23): 5347-5356.
39. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancy J, Hidalgo M, Walsh D: Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: a North Central Cancer Treatment Group Study. *J Clin Onc.* 2005; 23(23): 5294-5304.
40. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore Jr DF, Krook JE, Rowland KM, Mazurczak MA, Berg AR, Kim GP: Evaluation Of Shark Cartilage In Patients with Advanced Cancer: a North Cancer Clinical Trial Group Trial. *Cancer.* 2005;104(1):176-182.
41. Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, Dakhil SR, Moore T, Fitch TR: 5-Hydroxytryptamine-Receptor Antagonists Versus Prochlorperazine For Control Of Delayed Nausea Caused By Doxorubicin: a URCC CCOP Randomized Controlled Trial. *Lancet Oncol.* 2005 Oct 6;(10):765-772.
42. Moreno-Aspitia A, Colon-Otero G, Hoering A, Tefferi A, Niedringhaus R, Vukov A, Li CY, Menke DM, Geyer S, Alberts SR, Dakhil SR, Wos EJ, Morton RF, Fitch TR: Thalidomide Therapy in Adult Patients with Myelodysplastic Syndrome: a North Central Cancer Treatment Group Phase II Trial. *Cancer.* 2005.
43. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. *N Eng J Med.* 2005 Oct 20;353(16):1673-1684.
44. Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW: Phase III Comparison Of Depomedroxyprogesterone Acetate To Venlafaxine For Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7. *J Clin Onc.* 2006 Mar 20;24(9):1409-1414. Epub 2006 Feb 27.
45. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH: Oxaliplatin, Fluorouracil, And Leucovorin For Patients with Unresectable Liver-Only Metastases From Colorectal Cancer: a North Central Cancer Treatment Group Phase II Study. *J Clin Onc.* 2005 Dec 20;23(36):9243-9249. Epub 2005 Oct 17.
46. Barlogie B, Kyle R, Anderson K, Greipp P, Lazarus H, Hurd D, McCoy J, Moore, Jr. D, Dakhil S, Lanier K, Chapman R, Cromer J, Salmon S, Durie B, Crowley J: Standard Chemotherapy Compared with High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321. *J Clin Oncol.* 2006 Feb 20;24(6):929-936. Epub 2006 Jan 23.
47. Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH: A Phase II Evaluation of a 3-Hour Infusion of Paclitaxel, Cisplatin and 5-Fluorouracil In Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (SWOG S0007). *Cancer.* 2006 Jul 15;107(2):319-327.

48. Williamson SK, McCoy SA, Gandara DR, Dakhil SR, Yost KJ, Paradelo JC, Atkins JN, Glanke CD, Abbruzzese JL: Phase II Trial Of Gemcitabine Plus Irinotecan In Patients with Esophageal Cancer. a Southwest Oncology Group (SWOG) Trial. *Am J Clin Onc.* 2006 Apr;29(2):116-122.
49. Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhil SR, Abbruzzese JL: A Phase II Trial Of Etoposide B Analogue BMS-247550 (NSC#710428) Ixabepilone, In Patients with Advanced Pancreas Cancer: a Southwest Oncology Group Study. *Invest New Drugs.* 2006 Nov;24(6):515-520.
50. Haberman TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ: Rituximab-CHOP versus CHOP Alone Or with Maintenance Rituximab In Older Patients with Diffuse Large B-Cell Lymphoma. *J Clin Onc.* 2006 Jul 1;24(19):3121-3127. Epub 2006 Jun 5.
51. Sideras K, Schaffer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny P, Loprinzi CL: Low-Molecular-Weight Heparin In Patients with Advanced Cancer: a Phase 3 Clinical Trial. *Mayo Clin Proc.* 2006 Jun;81(6):758-767.
52. Clark MM, Hurt RD, Croghan IT, Patten CA, Novotny P, Sloan JA, Dakhil SR, Groghan GA, Wos EJ, Rowland KM, Bernath A, Morton RF, Thomas SP, Tschetter LK, Garneau S, Stella PJ, Ebbert LP, Wender DB, Loprinzi CL: The Prevalence Of Weight Concerns In a Smoking Abstinence Clinical Trial. *Addict Behav.* 2006 Jul;31(7):1144-1152. Epub 2005 Aug 30.
53. Dy GK, Jett JR, Geoffroy FJ, Krewer KD, Tazelaar H, Maurer M, Rowland K, Mailliard J, Krook J, Dakhil S, Kutteh L, Kugler J, Wender D: Topotecan and Paclitaxel in Previously Treated Patients with Relapsed Small Cell Lung Cancer: Phase II Trial of the North Central Cancer Treatment Group. *J Thor Onc.* 2006;1(3):211-7.
54. Jatoi A, Hillman S, Stella P, Rowland K, Morton R, Dakhil S. Why do oncologists prescribe--or not prescribe--conventional chemotherapy to geriatric patients with metastatic non-small cell lung cancer? *J Support Oncol.* 2006. Jul-Aug;4(7):311-2. PubMed PMID: 16892691.
55. Belani CP, Dakhil S, Waterhouse DM, Desch CE, Rooney DK, Clark RH, Monberg, MJ, Ye Z, Obasaju CK. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. *Ann Oncol.* 2007 Jan;18(1):110-5. Epub 2006 Oct 16. PubMed PMID: 17043094.
56. Hesketh PJ, McCoy J, Dunphy FR, Bearden JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara DR: Phase II Trial of Paclitaxel, Carboplatin and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914. *J Thor Oncol.* 2006 Nov;1(9):991-995.
57. Giordano KF, Jatoi A, Stella PJ, Foster N, Tschetter LK, Alberts SR, Dakhil SR, Mailliard JA, Flynn PJ, Nikcevich DA. Docetaxel And Capecitabine In Patients with Metastatic Adenocarcinoma Of The Stomach And Gastroesophageal Junction: a Phase II Study Of The North Central Cancer Treatment Group. *Ann Oncol.* 2006 Apr;17(4):652-656. Epub 2006 Feb 23.
58. Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young C, Tan W. A Tomato-Based, Lycopene-Containing Intervention For Androgen-Independent Prostate Cancer: Results Of a Phase II Study From The North Central Cancer Treatment Group. *Urology.* 2007;69(2):289-294.
59. Jatoi A, Nguyen PL, Foster N, Sun D, Stella PJ, Campbell M, Tschetter LK, Dakhil SR, Mailliard JA, Nikcevich DA. Interleukin-1 Genetic Polymorphisms And Their Relationship To The Cancer Anorexia/Weight Loss Syndrome In Metastatic Gastric And Gastroesophageal Junction Adenocarcinoma. *J Supp Oncol.* 2007 Jan;5(1):41-46.
60. Croghan I, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, Wos EJ, Rowland KM, Nair S, Morton RF, Le-Lindqwister NA, Tschetter LK, Garneau SC, Flynn KA, Ebbert LP, Wender DB, Loprinzi CL. A Randomized Comparison Of a Nicotine Inhaler And Bupropion For Smoking Cessation And Relapse Prevention. *Mayo Clin Proc.* 2007 Feb;82(2):186-195.
61. Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM, Soori GS, Wender DB, Fitch TR, Novotny PJ, Loprinzi CL. A Placebo-Controlled Double Blind Trial Of Etanercept For The Cancer Anorexia/Weight Loss

- Syndrome; Results From N00C1 From The North Central Cancer Treatment Group. *Cancer*. 2007 Sep 15;110(6):1396-1403.
62. Haddock MG, Swaminathan R, Foster NR, Alberts SR, Hauge MD, Martenson JA, Fitch TR, Stella PJ, Tenglin RC, Schaefer PL, Dakhil SR. Gemcitabine, Cisplatin and Radiation Therapy for Patient with Locally Advanced Pancreatic Adenocarcinoma: a North Central Cancer Treatment Group phase II study, N9942. *J Clin Onc*. 2007 25:2567-2572.
 63. Chehab BM, Dakhil SR. Von Meyenberg complexes simulating diffuse liver metastasis in rectal carcinoma. *Med J Aust*. 2007 Sep 3;187(5):305. PubMed PMID:17767438.
 64. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Verdirame JD, Nikcevich DA, Warner DO, Novotny PJ, Kutteh LA, Dakhil SR, Wong GY. The Efficacy of Gabapentin in the Management of Chemotherapy-Induced Peripheral Neuropathy: a Phase III Randomized, Double-Blind, Placebo-Controlled, Crossover Trial (N00C3). *Cancer*. 2007 Nov 1;110(9):2110-2118.
 65. Gotay CC, Moinpour CM, Unger JM, Jiang CS, Coleman D, Martino S, Parker BJ, Bearden JD, Dakhil SR, Gross HM, Lippman S, Albain KS. Impact Of a Peer-Delivered Telephone Intervention For Women Experiencing a Breast Cancer Recurrence. *J Clin Onc*. 2007;25(15):2093-2099.
 66. Petersdorf SH, Rankin C, Head DR, Terebelo HR, Willman CL, Balcerzak SP, Kamad A, Dakhil S, Appelbaum FR. Phase II Evaluation of an Intensified Induction Therapy with Standard Daunomycin and Cytarabine Followed by High Dose Cytarabine for Adults with Previously Untreated Acute Myeloid Leukemia: a Southwest Oncology Group Study (SWOG-9500). *Am J Hematol*. 2007;82:1056-1062.
 67. Chehab BM, Dakhil SR, Nassif II. Melanoma metastatic to the duodenum presenting as upper GI bleed: 2 cases and a review of the literature. *Gastrointest Endosc*. 2008 May;67(6):998-1000. doi: 10.1016/j.gie.2007.09.045. Epub 2008 Jan 31. PubMed PMID: 18241862.
 68. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas E, Wolmark N. Preoperative Chemotherapy: Updates Of National Surgical Adjuvant Breast And Bowel Project Protocols B-18 And B-27. *J Clin Onc*. 2008;26(5):778-785.
 69. Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS. Late Cardiac Effects Of Adjuvant Chemotherapy In Breast Cancer Survivors Treated On Southwest Oncology Group (SWOG) Protocol S8897. *J Clin Oncol*. 2008;28(8): 1223-1230.
 70. Loprinzi CL, Barton DL, Sloan JA, Novotny PJ, Dakhil SR, Verdirame JD, Knutson WH, Kelaghan J, Christensen BJ. Mayo Clinic and North Central Cancer Treatment Group Hot Flash Studies: a 20 Year Experience. *J No Am Menopause Soc*. 2008;15(4 pt 1): 655-660.
 71. Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM Jr, Moore DF Jr, Jaslowski, AJ, Thomas SP, Hauge MD, Flynn PJ, Stella PJ, Alberts SR. Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). *J Thorac Oncol*. 2008 May;3(5):516-20. doi: 10.1097/JTO.0b013e31816de276. PubMed PMID: 18449005; PubMed Central PMCID: PMC3929582.
 72. Beer, TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ Jr, Dakhil SR, Lara PN Jr, Drelichman A, Hussain MH, Crawford ED. Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes. *Clin Genitourin Cancer*. 2008 Sep;6(2):103-109.
 73. Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Dakhil SR, Kugler JW, Windschitl HE, Rowland KM, Bernath AM, Fitch TR, Soori G, Jett JR, Adjei AA, Perez EZ. Phase III Randomized, Double-Blind Study of Maintenance CAI or Placebo in Patients with Advanced Non-Small Cell Lung Cancer after Completion of Initial Therapy (NCCTG 97-24-51). *Lung Cancer*. 2008;60(2): 200-207.
 74. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH. Phase III Study of Immediate Compared with Delayed Docetaxel after

- Frontline Therapy with Gemcitabine Plus Carboplatin in Advanced Non-Small Cell Lung Cancer. *J Clin Onc.* 2009 Feb 1;27(4):591-598. Epub 2008 Dec 15.
75. Halyard MY, Pisansky TM, Dueck AC, Pierce L, Solin LJ, Marks LB, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Dakhil SR, Perez EA. Radiotherapy And Adjuvant Trastuzumab In Stage I-IIA Breast Cancer: Tolerability And Adverse Event Data From The North Central Cancer Treatment Group Phase 3 Trial N9831. *J Clin Onc.* 2009 June 1;27(16): 2638-2644. Epub 2009 Apr 6.
76. Sturgeon M, Wetta-Hall R, Hart T, Good M, Dakhil S. Effects of therapeutic massage on the quality of life among patients with breast cancer during treatment. *J Altern Complement Med.* 2009 Apr;15(4):373-80. doi: 10.1089/acm.2008.0399. PubMed PMID: 19388859.
77. Kearns AE, Northfelt DW, Dueck AC, Atherton PJ, Dakhil SR, Rowland KM, Fuloria J, Flynn PJ, Dentshev T, Loprinzi CL. Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: Placebo-Controlled Double-Blind Study Of Estradiol and Risedronate: N01C8. *Supp Care Cancer.* 2010 Mar;18(3):321-328. Epub 2009 May 27.
78. Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman CI, Kopecky KJ, Appelbaum FR. Sequential Phase II Southwest Oncology Group Studies (S0112 And S0301) of Daunorubicin and Cytarabine by Continuous Infusion, Without and with Cyclosporine, in Older Patients with Previously Untreated Acute Myeloid Leukaemia. *Br J Haematol.* 2010 Jan;148(1):48-58. Epub 2009 Oct 11.
79. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D. Cetuximab and First-Line Taxane/Carboplatin Chemotherapy In Advanced Non-Small Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099. *J Clin Onc.* 2010; 28(6): 911-927.
80. Loprinzi CL, Qin R, Balcueva EP, Flynn KA, Rowland KM, Graham DL, Erwin NK, Dakhil SR, Jurgens DJ, Burger KN. Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation Of Pregabalin For Alleviating Hot Flashes, N07C1. *J Clin Onc.* 2010;28(10): 1808.
81. Boccia RV, Cosgriff TM, Headley DL, Badarinath S, Dakhil SR. A Phase II Trial of FOLFOX6 and Cetuximab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer. *Clin Colorectal Can.* 2010;9(2): 102-107.
82. Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH. Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1. *J Clin Onc.* 2011;29(11):1472-1478.
83. Perez EA; Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zukewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer. *J Clin Onc.* 2011;29 (34): 4491-4497.
84. Saltz L, Badarinath S, Dakhil S, Bienvenu B, Harker WG, Birchfield G, Tokaz LK, Barrera D, Conkling PR, O'Rourke MA, Richards DA, Reidy D, Solit D, Vakianim E, Capanu M, Scales A, Zhan F, Boehm KA, Asmar L, Cohn A. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. *Clin Colorectal Cancer.* 2012 Jun;11(2):101-11. doi: 10.1016/j.clcc.2011.05.006. Epub 2011 Nov 4. PubMed PMID: 22055112.
85. Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, Yardley DA. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. *Breast Cancer Res Treat.* 2012 Jun;133(3):1067-75. doi: 10.1007/s10549-012-2008-6. Epub 2012 Mar 14. PubMed PMID: 22415477.
86. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE Jr, Swain SM, Costantino JP, Mamounas EP, Wolmark N. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. *Lancet Oncol.* 2012 Jul;13(7):734-42. doi: 10.1016/S1470-2045(12)70226-7. Epub 2012 Jun 14.

87. McCahill LE, Yothers G, Sharif S, Petrelli NK, Lai LI, Bechar N, Giguere JK, Dakhil SR, Fehrenbacher L, Lopa SH, Wagman LD, O'Connell MJ, Wolmark N. Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting with Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10. *J Clin Onc.* 2012 Aug 6:30 (24).
88. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. *N Eng J Med.* 2012 Aug 2: 367:435-444.
89. Aisner J, Manola JB, Dakhil SR, Stella PJ, Sovak MA, Schiller JH. Vandetanib plus Chemotherapy for Induction Followed By Vandetanib or Placebo as Maintenance for Patients with Advanced Non-Small Cell Lung Cancer: a Randomized Phase 2 Precog Study (Pre0501). Presented in part at EORTC/NCI/ASCO 2010, IASLC 2011, and ASCO 2011. Results last updated November 28, 2012, posted in clinicaltrials.gov (NCT 00687297).
90. Moreno-Aspitia A, Dueck AC, Ghanem-Canete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA. RC0639: Phase II Study Of Paclitaxel, Trastuzumab And Lapatinib As Adjuvant Therapy For Early Stage HER2-Positive Breast Cancer. *Br Can Res and Treatment.* 138(2): 427-435.
91. Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil, SR, Page RD, Orsini J, Zhang H and Renschler MF: Safety And Efficacy Of Weekly Nab-Paclitaxel In Combination with Carboplatin As First-Line Therapy In Elderly Patients with Advanced Non-Small-Cell Lung Cancer. *Annals of Onc.* 2013 Feb;24(2):314-321.
92. Ramalingam S, Perol M, Reck M, Kowalyszyn R, Gautschi O, Kimmich M, Cho EK, Grigorescu A, Karaseva N, Dakhil S, Lee P, Zimmerman A, Sashegyi A, Alexandris E, Carter G, Winfree K, Garon E: Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. *Clinical Lung Ca*, Epub 2017 Dec 10; 10.1016/j.clcc.2017.12.011
93. Halle C. F. Moore, et. al.: Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). DOI: 10.1200/ jco.2014.32.18
94. Corey Langer, Edward Kim, Eric C. Anderson, Robert M. Jotte, Manuel Modiano, Daniel E. Haggstrom, Matei P. Socoteanu, David A. Smith, Christopher Dakhil, Kartik Konduri, Tymara Berry, Teng J. Ong, Alexandra Sanford, Katayoun Amiri, Jonathan W. Goldman, Jared Weiss: nab-Paclitaxel-Based Regimens in Underserved Patient Populations Part 1: The ABOUND.70+ Study in Elderly Patients with Advanced NSCLC. *Frontiers in Oncology, Thoracic Oncology.* Epub 2018 July 24; doi: 10.3389/fonc.2018.00262

Other scholarly publications - Abstracts:

1. Dakhil S, Ensminger W, Kindt G: Maintenance of Constant CSF MTX Levels with a Totally Implanted Infusion System. Proceedings of the American Association for Cancer Research (AACR) 1980;21:149.
2. Greenberg H, Ensminger W, Seeger JF, Kindt G, Dakhil S: Escalating Doses of Intracarotid BCNU for Malignant Gliomas. *Clin Res.* 1980 Oct;28:743A.
3. Ensminger W, Dakhil S, Cho K: Improved Regional Selectivity of Hepatic Arterial BCNU plus Degradable Starch Microspheres. Proceedings of the American Society for Clinical Oncology (ASCO) 1981:22:382.
4. Keller J, Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R: Effective Prolonged Hepatic Arterial Chemotherapy Using a Totally Implanted Delivery System. Proceedings of the ASCO 1981:22:178, C87.
5. Dakhil S, Ensminger W, Strother V, Kindt G, Chandler W, Greenberg H: Pharmacokinetics Of Intraventricular 5-Fluoro-2'deoxyuridine (FUDR) In Patients with Meningeal Neoplasia. Proceedings of the AACR 1981:22:178, C706.
6. Ensminger W, Dakhil S, Doan K, Cho K: Clinical Pharmacology of Dichloromethotrexate in Hepatic Arterial Infusions. Proceedings of the AACR 1981:22:271, C1077.

7. Housholder D, Hynes H, Dakhil S, Marymont J: Hepatobiliary Scintigraphy In Patients Receiving Hepatic Artery Infusion Chemotherapy. Society of Nuclear Medicine, June 1984.
8. Dakhil S, Zatzkin J, Kim P, Hynes H: Digital Subtraction Angiography in the Evaluation of Malpositioned Hepatic Artery Catheter. Proceedings of the ASCO 1984:3:C-542.
9. Dakhil S, Hynes H, Kim P, Zatzkin J: Wichita Community Experience with The Infusaid Pump For Chemotherapy Of Liver Malignancies. Proceedings of the American College of Physicians Kansas Regional Meeting, Kansas City, Missouri, February 1983.
10. Dakhil S, Hynes H, et al: Secobarbital Combination, An Effective Antiemetic Regimen in Patients Receiving Platinum. Proceedings of the ASCO 1985:4:270, C1049.
11. Dakhil S, Hynes H, Zatzkin J: Wichita Community Experience with the Implantable Catheter (Port-A-Cath). Proceedings of the ASCO 1985:4:270, C1050.
12. Balducci, Dakhil S, et al: Evaluation of Fludarabine Phosphate in Renal Cell Carcinoma. Proceedings of the ASCO 1985:4:100, C429.
13. Morrow GR, Pandya K, Barry M, DiFino S, Jennings P, Flynn P, Rosenbluth R, Dakhil S: Chemotherapy-Induced Fatigue and Patient-Reported Psychological Depression (Meeting Abstract). Proceedings of the Annual Meeting of the ASCO 1992, #A1329.
14. Dakhil SR, Hynes HE, Cannon MW, Johnson DB, Moore DF Jr: G-CSF Plus Ciprofloxacin In The Prevention Of Sepsis In Patients with Severe Neutropenia Related To Chemotherapy. *Blood*. 1994:84(Suppl 1):24a(#83). Proceedings of the American Society of Hematology, 1994.
15. Moore DF Jr, Moore DF Sr, Johnson DB, Cannon MW, Whisman SA, Church PS, Palko W, Dakhil SR, Hynes HE: Bethesda Unit Titer As a Prognostic Factor For Patients with Acquired Factor VIII Inhibitors. *Blood*. 1994:84(Suppl 1):680a(#2705).
16. Pazdur R, Bready B, Diaz-Canton E, Gray R, Belt W, Goodwin SR, Dakhil SR, Fueger R, Winn R, Ajani JA. Sequential Modulation of Fluorouracil with Leucovorin, PALA, and Alpha Interferon: Phase II Trial in Advanced Colorectal Carcinoma. Proceedings of the ASCO 1995:14:208(#510).
17. Fossella FV, Lee JS, Winn R, Wester M, Graham S, Holder LW, Goodwin JW, Dakhil SR, Hong WK. Edatrexate (E) + Ifosfamide (I) + Cisplatin (P) with Leucovorin (LV) and Mesna (M) For Advanced Non-Small Cell Lung Cancer (NSCLC). Proceedings of the ASCO 1995:14:371(#1145).
18. Moore DF Jr, Moore DF Sr, Johnson DB, Bluml P, Cannon MW, Dakhil SR, Palko W, Hynes HE. Interleukin-2 (IL-2) Therapy Following Autologous Blood and Marrow Transplantation in Burkitt's Lymphoma: Effect On Lymphocyte Subsets. Proceedings of the 2nd Pan-Pacific Lymphoma Conference 1995, (abstr)[In Press].
19. Whitehead RP, Blumenstein B, Flanigan RC, Weiss GR, Culkin DJ, Bearman SI, Dakhil SR, Crawford ED. Phase II Trial Of Recombinant Human Interleukin-4 (Rhuil-4) In Patients with Disseminated Renal Cell Adenocarcinoma: a Southwest Oncology Group (SWOG) Study. ASCO 1996: 15:259(#672).
20. Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakhil S, Jaeckle KA, Levin VA. TPDC-FuHu Chemotherapy for the Treatment of Recurrent Metastatic Brain Tumors. *J Clin Onc*. 1997 Mar 1:1063-70.
21. Increased Intensification and Total Dose of cyclophosphamide in a Doxorubicin-Cyclophosphamide Regimen for the Treatment of Primary Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-Special participation from Shaker R. Dakhil. *J Clin Onc*. 1997 May;(15):1858-1869.
22. Medgyesy, D., Dakhil, S., Moore, D., Scalzo, A., Hoff, P.M., Abbruzzese, J., Winn, R., Pazdur, R., M.D. Anderson Cancer Center, Houston, TX 77030, Wichita CCOP, Wichita, KS 67214, Syracuse CCOP, Syracuse, NY 13210. 9-AC Study; NCI-EORTC Symposium, 1998.
23. Loesch D, Robert N, Dakhil S, Gusfey G, Hopkins J, Rohrbaugh T. Phase II Trial of a Weekly Taxol (T), 5-Fluorouracil (FU) and Leucovorin (LV) Regimen in Patients (Pts) with Metastatic Breast Cancer: An Update. Presented at ASCO. 1999:18:117a(#445).

24. Robert N, Loesch D, Dakhil S, Lee M, Rohrbaugh T. Phase II Trial of Weekly Taxotere (T), 5-Fluorouracil (FU), and Leucovorin (LV) in Patients with Advanced Breast Cancer. Presented at ASCO 1999:18:119a(#451).
25. Garfield D, Dakhil S, Abubakr Y, Druger S, Frank S: Phase II Trial of Carboplatin (CP) and Etoposide (E) Induction Therapy (IT) Followed By Weekly Taxol (T) Maintenance Therapy (MY) in Patients (pts) with Extensive Stage Small Cell Lung Cancer (ESSCLC). Proceedings of ASCO 1999:18:505a(#1945).
26. Hoff P, Ellerton JA, Dakhil SR, Winn RJ, Abbruzzese JL, Pazdur R. Phase II Study of Intravenous CI-958 in Metastatic Colorectal Adenocarcinoma. The University of Texas M.D. Anderson Cancer Center, Houston, Texas, Southern Nevada CCOP, and Wichita CCOP, Wichita, Kansas.
27. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Norton L, Allred C, Dakhil S, Pierce T, Goodwin J, Thompson I, Rivikin S, Chapman R, Osborne K. CMF Versus CAF with and Without Tamoxifen in High-Risk Node-Negative Breast Cancer Patients and a Natural History Follow-up Study in Low-Risk Node-Negative Patients. First Results of Intergroup Trial INT 0102. a Southwest Oncology Group Operations Office, San Antonio, Texas.
28. Hynes HE, Dakhil SR, Fisher EI, Coltman Jr CA, Godfrey MA. Phase II Trial of Estramustine and Etoposide in Hormone Refractory Prostate Cancer. a Southwest Oncology Group Trial (SWOG-9407).
29. Dakhil SR, Logie KW, Marsland TA, Simon SR, Weinstein RE, Khan MM. Phase II Trial Of Doxil In Patients with Refractory/Relapsed Low Grade Non-Hodgkin's Lymphomas. American Society of Hematology. 2000. Abstract #4750.
30. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVassur BI, Barton DL, Novotny PJ, Dakhil SR, Kardinal CG, Christensen BJ, Rodger K, Rummans T. Venlafaxine Alleviates Hot Flashes. (slide presentation) Proceedings ASCO 19:2a (2000).
31. Hussein MA, Gundacker H, Elias L, Dakhil SR, Head DR, Applebaum FR. Encouraging Response Rate to Sequential Cyclophosphamide (Cy) Followed by Fludarabine Phosphate (FI) In Newly Diagnosed B-Cell Chronic Lymphocytic Leukemia (CLL): a Southwest Oncology Group Trial. Proc Am Soc Clin Oncol 2001;20:305a(#1217).
32. Alberts SR, Horvath W, Donohue JH, Sternfeld W, Goldberg RM, Mahoney MR, Nagorney DM, Levitt R, Dakhil SR, Rowland K, Sargent DJ. Oxaliplatin (OXAL), 5-Fluorouracil (5FU), And Leucovorin (CF) For Patients with Liver Only Metastases From Colorectal Cancer: a North Central Cancer Treatment Group (NCCTG) Phase II Study. Proceedings of ASCO 20:129a, 2001.
33. Klein CE, Tangen CM, Braun TJ, Hussain M, Budd GT, Nichols CR, Rivikin SE, Dakhil SR, Crawford ED. Evaluation of Topotecan in Hormone Refractory Prostate Cancer: a South West Oncology Group Study. (SWOG 9510).
34. Hussein MA, Gundacker H, Elias L, Dakhil SR, Head DR, Appelbaum F. Encouraging Response Rate To Sequential Cyclophosphamide (CY) Followed By Fludarabine Phosphate (FI) In Newly Diagnosed B-Cell Chronic Lymphocytic Leukemia (B-CLL). Proc Am Soc Clin Oncol, 20:305a (#1217), 2001.
35. Velasquez WS, Lew D, Grogan TM, Kuebler JP, Balcerzak SP, Dakhil SR, Miller TP, Lanier KS, Chapman RA, Fisher RI. Combination of Fludarabine and Mitoxantrone in Untreated Stages III/IV Low-Grade Lymphoma: a Southwest Oncology Group Study (SWOG 9501).
36. Perez EA, Hillman DW, Fishkin P, Krook JE, Alberts SR, Dakhil SR. Phase II Trial of Dolastatin-10 in Patients with Advanced Breast Cancer. a North Central Cancer Treatment Group and Mayo Clinic.
37. Jatoi A, Dakhil SR, Burch PA, Mattar BI, Sloan JA, Fitch TR, Novotny PJ, Camoriano JK, Young CY, Rowland KM, Quevedo F, Tan WW. A Phase II Trial Of Green TeClinical Utility of Genomic Recurrence Risk
38. a For Androgen-Independent Prostate Cancer. a NCCTG Trial. Proc Am Soc Clin Oncol 2002.
39. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Buckner JC, Fitch TR, Rowland, KM, Kugler JW, Dakhil SR. Randomized Phase II Study Of Two Schedules Of Irinotecan (CPT-11) For Patients with Refractory Metastatic Breast Cancer (MBC): An NCCTG Study. Proc Am Soc Clin Oncol 2002, 21:52a.
40. Burch PA, Alberts SR, Schroeder MT, Erlichman C, Dakhil S, Steen PD, Nair S, Cha S, Sargent DJ, Goldberg RM. Gemcitabine And ISIS-2503 For Patients with Pancreatic Adenocarcinoma (ACA): a North Central Cancer Treatment Group (NCCTG) Phase II Study. Proc Am Soc Clin Oncol 2003, 22:259(1038).

41. Jatoi A, Rowland KM, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny CL, Mailliard JA, Krook JE. An Eicosapentanoic Acid (EPA) – Enriched Supplement Versus Megestrol Acetate (MA) Versus Both For Patients with Cancer-Associated Wasting. Proc Am Soc Clin Oncol 2003, 22:743.
42. Alberts SR, Donohue JH, Mahoney MR, Horvath WC, Sternfeld WC, Dakhil SR, Levitt R, Rowland KM, Sargent DJ, Goldberg RM. Patterns Of Failure After Liver Resection In Patients Receiving FOLFOX4 For Metastatic Colorectal Cancer Limited To The Liver: a North Central Cancer Treatment Group Study. *European J Cancer.* 2003;Suppl 5:S80.
43. Alberts SR, Donohue JH, Mahoney MR, Horvath WC, Sternfeld WC, Dakhil SR, Levitt R, Rowland KM, Sargent DJ, Goldberg RM. Liver Resection After 5-Fluorouracil, Leucovorin And Oxaliplatin For Patients with Metastatic Colorectal Cancer (MCRC) Limited To The Liver: a North Central Cancer Treatment Group (NCCTG) Phase II Study. Proc Am Soc Clin Oncol 2003, 22:263(#1053).
44. Whitehead RP, McCoy S, MacDonald J, Rivkin SE, Neubauer M, Dakhil S, Lenz HJ, Tanaka M, Abbruzzese JL: Phase II Trial Of R115777 (NSC #70818) In Patients with Advanced Colorectal Cancer: a Southwest Oncology Group Study. Proc Am Soc Clin Oncol 2003, 22:272(#1092).
45. Ranson S, Morrow GR, Dakhil S, Wade JL, Fitch T, Roscoe J, Shelke A, Hickok JT: Internet Use Among 1020 Cancer Patients Assessed In Community Practices: a URCC CCOP Study. Proc Am Soc Clin Oncol 2003, 22:534(#2149).
46. Jett JR, Geoffroy FJ, Rowland KM, Maurer MJ, Dakhil S, Krook J. Topotecan (T) And Paclitaxel (P) In Previously Treated Patients with Refractory Or Relapsed Small Cell Lung Cancers (SCLC): a Phase II Trial Of The North Central Cancer Treatment Group. Proc Am Soc Clin Oncol 2003, 22:667(#2681).
47. Jatoi A, Rowland KM, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Malliard JA, Krook JE. An Eicosapentanoic Acid (EPA)-Enriched Supplement Versus Megestrol Acetate (MA) Versus Both For Patients with Cancer-Associated Wasting. a Collaborative Effort From The North Central Cancer Treatment Group (NCCTG) And The National Cancer Institute Of Canada. Proc Am Soc Clin Oncol 2003, 22:743(#2987).
48. Schulz TK, Geyer SM, Jatoi A, Castillo R, Fitch TR, Dakhil SR, Rowland KM, Nair SR, Krook JE, Kugler JW. Oral Vinorelbine In Elderly Patients (> 65 Years Old) with Advanced Non-Small Cell Lung Cancer (NSCLC): a Phase II Trial From The North Central Cancer Treatment Group. Proc Am Soc Clin Oncol 2003, 22:752(#3022).
49. Loprinzi CL, Levitt R, Barton D, Sloan J, Atherton P, Dakhil S, Nikcevic DA, Rowland KM, Tschetter LK, Mailliard JA, Fitch TR. Evaluation of Benefin Shark Cartilage in Patients with Advanced Cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
50. Moreno-Aspitia A, Tefferi A, Niedringhaus R, Colon-Otero G, Vukov A, Li CY, Menke DM, Geyer S, Hoering A, Alberts SR, Dakhil SR, Wos EJ, Morton RF, Fitch TR. Thalidomide Therapy In Adult Patients with Myelodysplastic Syndrome: a North Central Cancer Treatment Group (NCCTG) Phase II Trial.
51. Worden FP, Moon J, Samlowski W, Clark J, Dakhil SR, Taylor SA, Urba SG, Hussain M. A Phase II Evaluation Of a 3-Hour Infusion Of Paclitaxel (P), Cisplatin (CDDP) & 5-Fluorouracil (5-FU) In Patients with Advanced Or Recurrent Squamous Cell Carcinoma Of The Head And Neck (SCCHN). a Southwest Oncology Group (SWOG) Study. Proc of the ASCO 23:489(#5512) (2004).
52. Miller DV, Jenkins RB, Lingle W, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Perez EA. Focal HER2/New Amplified Clones Partially Account For Discordance Between Immunohistochemistry And Fluorescence In Situ Hybridization Results. Proc ASCO 22:19s. (2004).
53. Kim GP, Alberts SA, Tschetter LK, Fitch TR, Dakhil SR, Morlan BW, Sargent D. Gemcitabine And Docetaxel In Patients with Measurable Unresectable Or Metastatic Hepatocellular Carcinoma. Proc ASCO 22:380s. (2004).
54. Call TG, Constantinou CL, Kahanic SP, Rowland KM, Dakhil SR, Hoering A, Li CY, Dewald GW, Kay NE, Witzig TE. Trial Of Gemcitabine For Relapsed B-Cell Chronic Lymphocytic Leukemia. Proc ASCO 22:613s. (2004).
55. Goetz MP, Jatoi A, Geyer SM, Safgren SL, Kuffel MJ, Adjei AA, Castillo RA, Dakhil SR, Fitch TR, Ames MM. MDRI And CYP2A5 Polymorphisms And Clinical Outcome In Elderly Patients Treated with Oral Vinorelbine As First-Line Therapy For Metastatic Non-Small Cell Lung Cancer. AACR (2004).
56. Habermann TM, Weller E, Morrison VA, Cassileth PA, Cohn JB, Dakhil SR, Gascoyne RD, Woda B, Fisher RI, Peterson BA, Horning S. Rituximab-CHOP Vs CHOP with Or Without Maintenance Rituximab In Patients 60 Years Of Age Or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update Am Soc Hematology 2004. Abstract 127. [E4494]

57. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR. Randomized Phase II Study Of Two Irinotecan Schedules For Patients with Metastatic Breast Cancer Refractory To An Anthracycline, a Taxane, Or Both. *J Clin Onc.* 2004 July 15:2849-2855.
58. Perez, EA, Suman VJ, Davidson NE, Kaufman A, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS. Effect Of Doxorubicin Plus Cyclophosphamide On Left Ventricular Ejection Fraction In Patients with Breast Cancer In The North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. *J Clin Onc.* 2004 Sep 15:3700-3704.
59. Witzig TE, Ansell SM, Geyer SM, Kurtin PJ, Rowland KM, Flynn PJ, Morton RF, Dakhil SR, Gross HM, Maurer MJ, Kaufmann SH. Antitumor Activity Of Low-Dose Single Agent CCI-779 For Relapsed Mantle Cell Lymphoma: a Phase II Trial In The North Central Cancer Treatment Group. Proc of the ASCO 23:561s (2005).
60. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH. Phase II Trial Of Single-Agent Temsirolimus (CCI-779) For Relapsed Mantle Cell Lymphoma. *J Clin Onc.* 2005 Aug 10:5347-5356.
61. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Baliman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancy J, Hidalgo M, Walsh DJ. Phase II Trial Of Temsirolimus (CCI-779) In Recurrent Glioblastoma Multiforme: a North Central Cancer Treatment Group Study. *J Clin Onc.* 2005 Aug 10:5294-5304.
62. Alberts SR, Horvath WL, Sternfeld WC, Goldbert RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, Fluorouracil And Leucovorin For Patients with Unresectable Liver-Only Metastases From Colorectal Cancer: a North Central Cancer Treatment Group Phase II Study. *J Clin Onc.* 2005 Dec 20:9243-9249.
63. Wong GY, Michalak JC, Sloan JA, Mailliard JA, Nikcevich DA, Warner D0, Loprinzi CL, Kutteh LA, Dakhil SR. A Phase III Double-Blinded, Placebo Controlled Randomized Trial Of Gabapentin In Patients with Chemotherapy-Induced Peripheral Neuropathy. Proc of the ASCO 23:729s (2005).
64. Loprinzi CL, Levitt R, Sloan JA, Dakhil SR, Barton DL, Dalton RJ, Beardem JD, Mailliard JA, Tschetter LK, Novotny PJ. Medroxyprogesterone Acetate (MPA) Versus Venlafaxine For Hot Flashes. Proc of the ASCO 23:732s (2005).
65. Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW. Phase III Comparison Of Depomedroxyprogesterone Acetate To Venlafaxine For Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7. *J Clin Onc.* 2006 Mar 20:1409-1414.
66. Dakhil S, Cosgriff T, Headley D, Boccia RV, Bandarinath BS. Cetuximab + FOLFOX6 As First Line Therapy For Metastatic Colorectal Cancer (An International Oncology Network Study, I-03-002). Poster Session ASCO, June 2006, #3557.
67. Kelly K, Herbst RS, Crowley JJ, McCoy J, Atkins JN, Lara PN, Dakhil SR, Albain KS, Kim ES, Gandara DR. Concurrent Chemotherapy Plus Cetuximab Or Chemotherapy Followed By Cetuximab In Advanced Non-Small Cell Lung Cancer (NSCLC): a Randomized Phase II Selectional Trial SWOG 0342. Oral presentation ASCO Meeting, June 2006, #7015.
68. Fidias P, Dakhil SR, Lyss AP, Loesch DM, Waterhouse D, Cunneen J, Ye Z, Tai F, Obasaju CK, Schiller JH. Updated Report Of a Phase III Study Of Induction Therapy with Gemcitabine + Carboplatin (GC) Followed By Either Delayed Vs Immediate Second-Line Therapy with Docetaxel (D) In Advanced Non-Small Cell Lung Cancer (NSCLC). Poster Discussion ASCO Meeting, June 2006, #7032.
69. Ansell SM, Geyer SM, Kurtin PJ, Inwards DJ, Kaufmann SH, Flynn PJ, Morton RF, Luyun RF, Dakhil SR, Gross H, Witzig TE. Anti-Tumor Activity Of mTOR Inhibitor Temsirolimus For Relapsed Mantle Cell Lymphoma: a Phase II Trial In The North Central Cancer Treatment Group. Poster Discussion ASCO Meeting, June 2006, #7532.
70. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, Michalak JC, Salim M, Nikcevich DA, Dakhil SR, Fitch TR. Salvage chemotherapy with Rituximab DHAP (RDHAP) for relapsed non-Hodgkin's lymphoma (NHL): a phase II trial in the North Central Cancer Treatment Group. General Poster Session ASCO Meeting, June 2006, #7574.
71. Hofman M, Morrow GR, Ranson SL, Jean-Pierre P, Dakhil SR, Moore T, Atkins J. Chemotherapy-Naive Cancer Patients' Expectations Of Developing Treatment-Related Side Effects: a URCC CCOP study of 670 patients from community practices. Oral presentation ASCO Meeting, June 2006, #8509.

72. Jatoi A, Dakhil SR, Kugler JW, Rowland KM, Keit J, Verdirame JD, Novotny PJ, Sloan JA, Nguyen PL, Loprinzi CL. A Placebo-Controlled Trial Of Etanercept, a Tumor Necrosis Factor (TNF) Inhibitor, In Patients with The Cancer Anorexia/Weight Loss Syndrome. North Central Cancer Treatment Group (NCCTG) Trial N00C1. Poster Discussion ASCO Meeting, June 2006, #8534.
73. Gotay CC, Moinpour CM, Unger JM, Jiang CS, Coleman D, Martino S, Parker BJ, Bearden JD, Dakhil S, Gross HM, Lippman S, Albain KS. Impact Of a Peer-Delivered Telephone Intervention For Women Experiencing a Breast Cancer Recurrence. *J Clin Onc.* 2007 May 20:2093-2099.
74. Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson P, Figueras C, Duane SF, Dakhil SR, Liu H, Loprinzi CL. A Pilot, Placebo-Controlled Evaluation Of American Ginseng (Panax Quinquefolius) To Improve Cancer-Related Fatigue: NCCTG N03CA. ASCO Oral Presentation: 9001. (2007).
75. Jatoi A, Rowland KM, Sloan JA, Gross HM, Fishkin PAS, Kahanic SP, Novotny PJ, Schaefer PL, Dakhil SR, Loprinzi CL. Does Tetracycline Prevent Or Palliate Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash? ASCO Oral Presentation: LBA9006. (2007).
76. Haddock MG, Kim GP, Foster NR, Bollinger JW, Stella PJ, Kugler JW, Dakhil SR, Alberts SR, Martenson JA. Phase II Study Of Oxaliplatin, 5-Fu And RT Followed By Gemcitabine In Patients with Unresectable Pancreatic Cancer. ASCO (2007).
77. Alberts SR, Morlan BW, Kim GP, Pitot HC, Quevedo F, Dakhil SR, Gross HM, Merchan JR, Roberts LR. NCCTG Phases II Trial (N044J) Of AXD2171 For Patients with Hepatocellular Carcinoma – Interim Review Of Toxicity. ASCO (2007).
78. Inwards DJ, Hillman DW, Fishkin PAS, White WL, Morton RF, Dakhil SR, Nikcevich DA, Wender DB, Fitch TR, Kurtin PJ. Phase II Study Of Rituximab And Cladribine (2-CDA) In Newly Diagnosed Mantel Cell Lymphoma. American Society of Hematology (2007).
79. Joppert M, Boccia R, Dakhil S, Steis R. A Preliminary Report Of a Phase II Trial Of Single-Agent Vinflunine As Second-Line Treatment Of Advanced Non-Small Cell Lung Cancer. ASCO:18156. (2007).
80. Herbst RS, Chansky K, Kelly K, Atkins JN, Davies AM, Dakhil SR, Albain KS, Kim ES, Crowley JJ, Gandara DR. A Phase II Randomized Selection Trial Evaluating Concurrent Chemotherapy Plus Cetuximab Or Chemotherapy Followed By Cetuximab In Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Final Report Of SWOG 0342. Proc of the ASCO: #7545. (2007).
81. Morrison V, Weller E, Haberman TM, Cassileth PA, Cohn JB, Dakhil SR, Gascoyne R, Woda B, Fisher R, Peterson B, Horning SJ. Maintenance Rituximab (MR) Versus Observation (OBS) After R-CHOP Or CHOP In Older Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Patients: An Intergroup E4494/C9793 Update. Proc of the ASCO: #8011. (2007).
82. Fidias P, Dakhil SR, Lyss AP, Loesch DM, Waterhouse D, Cunneen J, Chen R, Treat J, Obasaju CK, Schiller JH. Phase III Study Of Immediate Versus Delayed Docetaxel After Induction Therapy with Gemcitabine Plus Carboplatin In Advanced Non-Small Cell Lung Cancer: Updated Report with Survival. *J Clin Onc.* 2007 ASCO Annual Meeting Proceedings Part I. 25(18s):LBA7516.
83. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative Chemotherapy: Updates Of National Surgical Adjuvant Breast And Bowel Project Protocols B-18 And B-27. *J Clin Onc.* 2008 Feb 10:778-785.
84. Kottschade LA, Suman VJ, Amatruda T, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ, Markovic SN. A Phase II Trial Of Carboplatin And ABI-007 In Patients with Unresectable Stage IV Melanoma, N057E. Proc of the ASCO: #9044. (2008).
85. Jatoi A, Foster NR, Egner J, Burch P, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy B, Alberts SR. Elderly Patients with Metastatic Esophageal/Gastric Cancer: a Pooled Analysis Of Age-Based Outcomes From 8 Consecutive North Central Cancer Treatment Group (NCCTG) Therapeutic Trials. Proc of the ASCO: 26(May 20s) #9507. (2008).
86. Morrow GR, Jean-Pierre P, Roscoe JA, Heckler CE, Schwartzenberger PO, Giguere JK, Dakhil SR. A Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of a Eugeroic Agent In 642 Cancer Patients Reporting Fatigue During Chemotherapy: a URCC CCOP Study. Proc of the ASCO: #9512. (2008).

87. Barton DL, LaVasseur B, Sloan JA, Stella PJ, Flynn K, Dyar M, Dakhil SR, Atherton PJ, Diekmann B, Loprinzi CL. A Phase III Trial Of Evaluating Three Doses Of Citalopram For Hot Flashes: NCCTG trial N05C9. Proc of the ASCO: #9538. (2008).
88. Joppert M, Knapp M, Dakhil SR, Boccia RV, Steis R, Jones CM. A Phase II Trial Of Single-Agent Vinflunine As Second-Line Treatment For Advanced Non-Small Cell Lung Cancer (An International Oncology Network Study, #I-05-009). Proc of the ASCO: #19033. (2008).
89. Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy BR, Alberts SR. Meta-Analyses Of Randomized Trials Assessing The Interest Of Postoperative Adjuvant Chemotherapy In Gastric Cancer. Proc of the ASCO: #4543. (2008).
90. Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III Trial of Irinotecan/Cisplatin Compared with Etoposide/Cisplatin in Extensive-Stage Small Cell Lung Cancer: Clinical and Pharmacogenomic Results from SWOG S0124. *J Clin Onc*. 2009 May 20;27(15):2530-2535. Epub 2009 Apr 6.
91. Gandara D, Kim ES, Herbst RS, Moon J, Redman MW, Dakhil SR, Hirsch F, Mack PC, Franklin W, Kelly K. S0536: Carboplatin, Paclitaxel, Cetuximab And Bevacizumab Followed By Cetuximab And Bevacizumab Maintenance In Advanced Non-Small Cell Lung Cancer (NSCLC), a SWOG Phase II Study. *J Clin Onc*. 27:15s, abst. #8015, 2009.
92. Sukov W, Miller DV, Dueck A, Tenner KS, Jenkins RB, Kaufman PA, Davidson NE, Dakhil SR, Martino S, Roy V, Perez EA. Benefit Of Adjuvant Trastuzumab In Breast Cancer Patients with Focal HER2 Amplified Clones: Data From N9831 Intergroup Adjuvant Trial. *J Clin Onc*. 27:15s, abst #520, 2009.
93. Markovic SN, Suman VJ, Kottschade LA, Amatruda T, McWilliams RR, Dakhil SR, Nikevich DA, Morton RF, Fitch TR, Jaslowski AJ. A Phase II Trial Of Carboplatin And Nab-Paclitaxel (ABI-0007) In Patients with Unresectable Stage IV Melanoma, Final Data Form N057E. *J Clin Onc*. 27:15s, abst #9055, 2009.
94. Perez EA, Suman VJ, Davidson NE, Gralow J, Kaufman PA, Ingle JN, Dakhil SR, Zujewski JA, Pisansky TM, Jenkins RB. Results Of Chemotherapy Alone, with Sequential Or Concurrent Addition Of 52 Weeks Of Trastuzumab In The NCCTG N9831 HER-2 Positive Breast Cancer Trial. General Session, 2009 San Antonio Breast Cancer Symposium (December 9-13, 2009).
95. deVos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt P, Flowers C, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory S, Holladay C, Zhang T, Boral A. Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients with Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma. *J Clin Onc*. 2009 Oct 20:5023-5030. Epub 2009 Sep 21.
96. Loprinzi CL, Qin R, Stella PJ, Rowland KM, Kugler JW, Dakhil SR, Jurgens DJ, Burger KN. Pregabalin In Hot Flashes In Women: NCCTG Trial N07C1. *J Clin Onc*. 2010 Feb 1;27:15s, abst #9513:641-647.
97. Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu L, Horak CE, Dakhil SR, Hermann RC, Lynch TJ, Weber MR. Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small Cell Lung Cancer. *J Clin Onc*. 2010 Feb 20:918-927.
98. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil SR, Gorton S, Pautret V, Weber MR, Woytowicz D. Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099. *J Clin Onc*. 2010 Feb 20:911-917.
99. Loprinzi CL, Qin R, Balcueva EP, Flynn KA, Rowland KM Jr, Graham DL, Erwin NK, Dakhil SR, Jurgens DJ, Burger KN. Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes, N07C1. *J Clin Oncol*. 2010 Feb 1;28(4):641-647. Epub 2009 Nov 9.
100. Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy BR, Alberts SR. Older Versus Younger Patients with Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Stomach: a Pooled Analysis of Eight Consecutive NCCTG trials. *Int J Oncol*. 2010 Mar;36(3):601-606.
101. Boccia RV, Cosgriff TM, Headley DL, Badarinath S, Dakhil SR. A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients with Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2010 Apr;9(2):102-107.

102. Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL. Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women with Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy. *Breast.* 2010 Apr;19(2):92-96. Epub 2010 Jan 15.
103. Kirshner J, Dakhil SR, et al. Prevention Of Pegfilgrastim-Induced Bone Pain (PIP): a URCC CCOP Randomized, Double-Blind, Placebo-Controlled Trial Of 510 Cancer Patients. Proc of the ASCO: #9014. (2010)
104. Novotny P, Sekulic A, Loprinzi CL, Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NI, Dakhil SR, Mattar BI, Nikcevich DA. Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor-induced Rash? Results of a Placebo-controlled Trial from the NCCTG (N05C4). *Oncologist.* 2010;15(9):1016-1022. Epub 2010 Aug 26.
105. Jatoi A, Schild SE, Foster N, Henning GT, Dornfeld KJ, Flynn PJ, Fitch TR, Dakhil SR, Rowland KM, Stella PJ, Soori GS, Adjei AA. A Phase II Study of Cetuximab and Radiation in Elderly and/or Poor Performance Status Patients with Locally Advanced Non-Small Cell Lung Cancer (N0422). *Ann Oncol.* 2010 Oct;21(10):2040-2044. Epub 2010 Jun 21.
106. Herbst RS, Kelly K, Chansky K, Mack PH, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara. Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non-Small Cell Lung Cancer: Southwest Oncology Group Study S0342. *J Clin Onc.* 2010 Nov 1:4747-4754.
107. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ, Rowland, Jr. KM, Novotny PJ, Loprinzi CL. Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients with Chemotherapy-Associated Anemia *J Clin Onc.* 2011 Jan 1:97-105.
108. Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori G, Jaslowski AJ, Novotny PJ, Lachance DH. Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1. *J Clin Onc.* 2011 Apr 10:1472-1478.
109. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer. *J Clin Onc.* 2011 Dec 1;29(34):4491-4497.
110. Brufsky A, Valero V, Tiangco B, Dakhil SR, Brize A, Duenne AA, Bousfoul N, Rugo HS, Yardley DA. Bevacizumab (BEV) Plus Second-Line Taxane (TAX) Or Other Chemotherapy (CT) For Triple-Negative Breast Cancer (TNBC): Subgroup Analysis Of RIBBON 2. 2011 Breast Cancer Symposium. *J Clin Onc.* 29: 2011 (suppl 27: abstract 290).
111. Reeves B, Dakhil S, Sloan J, Berger K, Le-Lindqwister N, Soori G, Jaslowski A, Lachance D, Loprinzi C. N08C1: Paclitaxel-Associated Acute Pain Syndrome And Its Association On The Development Of Peripheral Neuropathy. *J Clin Oncol.* 29:2011 (suppl. abstract 9047).
112. Pruthi S, Qin R, Terstriepe S, Liu J, Loprinzi C, Shah T, Tucker K, Dakhil S, Bury M, Carolla R, Steen P, Vuky J, Bartin D. N08C7: The Evaluation Of Flaxseed For Hot Flashes, Results Of a Randomized, Controlled Trial. *J Clin Oncol.* 29:2011 (suppl. abstract CRA9015).
113. Lafky J, Bot B, Morlan B, Anderson S, Kumar S, Kimlinger T, Reynolds J, Stella P, Dakhil S, Loui W, Alberts S, Grothey A. N054C: Circulating Endothelial Cells In Metastatic Colorectal Cancer Patients Treated with Bevacizumab And Sorafenib. ASCO publication. *J Clin Oncol.* 29:2011 (suppl. abstract e14063).
114. Hubbard J, Alberts S, Loui W, Mahoney M, Roberts L, Smyrk T, Gatalica Z, Kumar S, Dakhil S, Flynn P, Bury M. N0745: Phase I Evaluation Of Sorafenib And Bevacizumab In First-Line Therapy In Hepatocellular Cancer. ASCO poster presentation. *J Clin Oncol.* 29:2011 (suppl. abstract 4116).
115. Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM Jr, Schaefer PL, Novotny PJ, Wender DB, Gross HM, Loprinzi CL. Prophylactic Tetracycline Does Not Diminish the Severity of Epidermal Growth Factor Receptor (EGFR) Inhibitor-induced Rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB). *Support Care Cancer.* 2011 Oct;19(10):1601-1607.

116. Mohile SG, Fan L, Gewandter JS, Mustian KM, Peppone LJ, Heckler CE, Hopkins JO, Dakhil SR, Miller J, Morrow GR. Falls, Physical Performance Deficits, And Functional Losses In Cancer Survivors with Chemotherapy-Induced Neuropathy (CIPN): a University Of Rochester CCOP Study. 2012 ASCO Annual Meeting. *J Clin Onc.* 30:2012 (suppl; abstract 9014).
117. Sideras K, Moreno-Aspitia A, Tenglin RC, Liu H, Lingle WL, Reinholz MM, Halling KC, Chen B, Gross GC, Mowat RB, Dakhil SR, Perez EA. Randomized Phase II Study Of Two Doses Of Pixantrone In Patients with Metastatic Breast Cancer (N1031, Alliance). 2012 ASCO Annual Meeting. *J Clin Onc.* 30:2012 (suppl; abstract 1083).
118. Renschler MF, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Zhang H, Socinski MA. Safety And Efficacy Analysis By Histology Of Weekly Nab-Paclitaxel In Combination with Carboplatin As First-Line Therapy In Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC). 2012 ASCO Annual Meeting. *J Clin Onc.* 30:2012 (suppl; abstract 7592).
119. Pruthi S, Qin R, Terstreip SA, Liu H, Loprinzi CL, Shah TR, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes: NCCTG N08C7. *Menopause.* 2012 Jan;19(1):48-53.
120. Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini JM, Zhang H, Renschler MF. Weekly Nab-Paclitaxel In Combination with Carboplatin In First-Line Therapy In Elderly Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC). 2012 ASCO Annual Meeting. *J Clin Onc.* 30:2012 (suppl; abstract 7590).
121. Brewster M, Hurst D, Chai A, Lee EJ, Upadhyaya GH, Dakhil SR. Pharmacokinetics (PK) And Pharmacodynamics (PD) Of Rituximab Administered By Faster Infusion In Patients with Previously Untreated Diffuse Large B-Cell (DLBCL) Or Follicular Lymphoma (FL). 2012 ASCO Annual Meeting. *J Clin Onc.* 30:2012 (suppl; abstract 6591).
122. Kirshner J, Dakhil SR, Heckler CE, Janelins MC, Hopkins JO, Coles C, Morrow GR. Prevention of Pegfilgrastim-induced Bone Pain. A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base. *J Clin Onc.* 2012 Jun 1:1974-1979.
123. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE Jr, Swain SM, Costantino JP, Mamounas EP, Wolmark N. Oral Clodranate For Adjuvant Treatment Of Operable Breast Cancer (National Surgical Adjuvant Breast And Bowel Project Protocol B-34): a Multicentre, Placebo-Controlled, Randomized Trial. *Lancet.* 2012 Jun 13.
124. Shah, MA, Cutsem EV, Kang Y, Dakhil SR, Satoh T, Chin K, Bang Y, Bu L, Bilic G, Ohtsu A. Survival Analysis According To Disease Subtype In AVAGAST: First-Line Capecitabine And Cisplatin Plus Bevacizumab (Bev) Or Placebo In Patients with Advanced Gastric Cancer. 2012 Gastrointestinal Cancers Symposium. *J Clin Onc.* 30:2012 (suppl 4, abstract 5).
125. Ryan JL, Heckler CE, Roscoe JA, Dakhil SR, Kirshner J, Flynn PJ, Hickok JT, Morrow GR. Ginger (Zingiber Officinale) Reduces Acute Chemotherapy-Induced Nausea: a URCC CCOP Study Of 576 Patients. *Support Care Cancer.* 2012 20 Jul;20(7):1479-1489.
126. Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM, Nair S. Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: a Phase II NCCTG Clinical Trial. *Am J Clin Oncol.* 2012 Aug;35(4):329-333.
127. Wade, JL, Dakhil SR, Baron AD, Rottey S, Millard FE, Daugaard G, Machiels JH, Conkright WA, Sharma S, Soetekouw PM, Yachnin J, Sengelov L, Van Veldhuizen P, Agarwala SS, Nguyen Q, Chadja M, Maison-Blanche P. A QTC Study Of Cabazitaxel In Patients with Advanced Solid Tumors. 2012 Genitourinary Cancers Symposium. *J Clin Onc.* 30:2012 (suppl. 5, abstract 257).
128. Kim GP, Foster NR, Haddock MG, Bollinger JW, Dakhil SR, Behrens RJ, Flynn PJ, Steen PD, Bury MJ, Stella PJ, Alberts SR. North Central Cancer Treatment Group Phase II Study Of Panitumumab, Chemotherapy, And External Beam Radiation In Patients with Locally Advanced Pancreatic Cancer. 2012 Gastrointestinal Cancers Symposium. *J Clin Onc.* 30:2012 (suppl 4, abstract 271).
129. Choy H, Schwartzberg LS, Dakhil SR, Garon EB, Choksi JK, Govindan R, Peng G, Koustenis A, Treat J, Obasaju CK. Phase II Study Of Pemetrexed Plus Carboplatin Or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy

- Followed By Pemetrexed Consolidation In Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non-Small Cell Lung Cancer. 2012 ASCO Annual Meeting. *J Clin Onc.* 30:2012 (suppl; abstract 7002); *J Thorac Oncol.* 2013 Aug 26.
130. Barton DL, Liu H, Dakhil SR, Linqvist BM, Sloan JA, Nichols CR, McGinn TW, Balcueva EP, Seeger GR, Loprinzi CL. Phase III Evaluation Of American Ginseng To Improve Cancer-Related Fatigue: NCCTG Trial N07C2. 2012 ASCO Annual Meeting. *J Clin Onc.* 30: 2012 (suppl: abstract 9001).
131. Kirshner J, Heckler C, Janeisins M, Dakhil S, Hopkins J, Coles C, Morrow G. Prevention of Pegfilgrastim-Induced Bone Pain: a Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base. *J Clin Onc.* 2012 Jun 1;30(16):1974-1979.
132. Roscoe JA, Heckler CE, Morrow GR, Mohile SG, Dakhil SR, Wade JL, Kuebler JP. Prevention of Delayed Nausea: a URCC CCOP Study of 1021 Patients Receiving Chemotherapy. *J Clin Onc.* 2012 Sep 20;30(27):3389-3395. Epub 2012 Aug 20.
133. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. *N Engl J Med.* 2012 Aug 2;367(5):435-444.
134. McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, Giguere JK, Dakhil SR, Fehrenbacher L, Lopa SH, Wagman LD, O'Connell MK, Wolmark N. Primary mFOLFOX6 Plus Bevacizumab Without Resection Of The Primary Tumor For Patients Presenting with Surgically Unresectable Metastatic Colon Cancer And An Intact Asymptomatic Colon Cancer: Definitive Analysis Of NSABP Trial C-10. *J Clin Onc.* 2012 Sep 10;30(26):3223-8.
135. Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, Novotny PJ, Lachance DH, Loprinzi CL. Further Data Supporting that Paclitaxel-Associated Acute Pain Syndrome is Associated with Development of Peripheral Neuropathy: NCCTG Trial N08C1). *Cancer.* 2012 Oct 15;118(20):5171-5178.
136. Hines S, Sloan JA, Atherton P, Perez E, Dakhil S, Johnson D, Reddy P, Dalton R, Mattar B, Loprinzi C. Zoledronic Acid For Treatment Of Osteopenia And Osteoporosis In Women with Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy. San Antonio Breast Cancer Symposium 2009: 2013 (N02C1).
137. Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Zhang H, Renschler MF. Safety And Efficacy Of Weekly Nab-Paclitaxel In Combination with Carboplatin As First-Line Therapy In Elderly Patients with Advanced Non-Small Cell Lung Cancer. *Ann Oncol.* 2013 Feb;24(2):314-321.
138. Barton DL, Burger K, Novotny PJ, Fitch TR, Kohli S, Soori G, Wilwerding MB, Sloan JA, Kottschade LA, Rowland KM Jr, Dakhil SR, Nikcevich DA, Loprinzi CL. The Use Of Ginkgo Biloba For The Prevention Of Chemotherapy-Related Cognitive Dysfunction In Women Receiving Adjuvant Treatment For Breast Cancer, N00C9. *Support Care Cancer.* 2013 Apr;21(4):1185-1192.
139. Srivastava G, Renfro LA, Behrens RJ, Lopatin M, Chao C, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim GP, Mazurczak M, Lee M, Alberts SR. Prospective Evaluation of a 12-Gene Assay On Treatment Recommendations In Stage II Colon Cancer Patients. Mayo Clinic Cancer Research Consortium; Genomic Health, Inc. 2013 Gastrointestinal Cancers Symposium, January 24-26, 2013 (abstr #453).
140. Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared with CHOP Chemotherapy Plus (131) Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. *J Clin Oncol.* 2013 Jan 20;31(3):314-320. Epub 2011 Dec 10.
141. Socinski MA, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Yamamoto N, Zhang H, Renschler MF. Safety And Efficacy Analysis By Histology Of Weekly Nab-Paclitaxel In Combination with Carboplatin As First-Line Therapy In Patients with Advanced Non-Small-Cell Lung Cancer. *Ann Oncol.* 2013 Jul 10. Epub ahead of print.
142. Barton DL, Liu H, Dakhil SR, Linqvist B, Sloan JA, Nichols CR, McGinn TW, Stella PJ, Seeger GR, Sood A, Loprinzi CL. Wisconsin Ginseng (Panax quinquefolius) to improve Cancer-Related Fatigue: a Randomized Double-Blind Trial, N07C2. *J Natl Cancer Inst.* 2013 Aug 21;105(16):1230-1238. Epub 2013 Jul 13.

143. Aisner J, Manola JB, Dakhil SR, Stella PJ, Sovak MA, Schiller JH. Vandetanib Plus Chemotherapy for Induction Followed by Vandetanib or Placebo as Maintenance for Patients with Advanced Non-Small-Cell Lung Cancer: a Randomized Phase 2 PrECOG Study (PrE0501). *J Thorac Oncol*. 2013 Aug; 8(8):1075-1083.
144. Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Brazier RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP +131iodine--tositumomab. *Clin Cancer Res*. 2013 Dec 1;19(23):6624-32. doi: 10.1158/1078-0432.CCR-13-1120. Epub 2013 Oct 15. PubMed PMID: 24130072; PubMed Central PMCID: PMC3872052.
145. Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR Jr, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. *J Thorac Oncol*. 2013 Dec;8(12):1519-28. doi: 10.1097/JTO.000000000000009. PubMed PMID: 24189513; PubMed Central PMCID: PMC4072123.
146. Pritchard KI, Burris HA 3rd, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csösz T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. *Clin Breast Cancer*. 2013 Dec;13(6):421-432.e8. doi:10.1016/j.clbc.2013.08.011. PubMed PMID: 24267730.
147. Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masudaa N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart M. Everolimus Plus Exemestane as First-Line Therapy in HR+, HER2- Advanced Breast Cancer in BOLERO-2. *Breast Cancer Res Treat*. 2014 Feb; 143(3): 459-67. Epub 2013 Dec 21.
148. Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengelov L, Van Veldhuizen P, Agarwala SS, Semond D, Chadja M, Shen L, Wade JL. An Open-Label Study to Investigate the Cardiac Safety Profile of Cabazitaxel in Patients with Advanced Solid Tumors. *Cancer Chemother Pharmacol*. 2014 Apr 10. Epub ahead of print.
149. Srivastava G, Renfro LA, Behrens RJ, Lopatin M, Chao C, Sori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim G, Mazurczak M, Lee M, Alberts SR. Prospective Multicenter Study of the Impact of Oncotype DX Colon Cancer Assay Results on Treatment Recommendations in Stage II Colon Cancer Patients. *Oncologist*. 2014 Apr 7. Epub ahead of print.
150. Dakhil S, Hermann R, Schreeder MT, Gregory SA, Monte M, Windsor KS, Hurst D, Chai A, Brewster M, Richards P. Phase III Safety Study of Rituximab Administered as a 90-Minute Infusion in Patients with Previously Untreated Diffuse Large B-cell and Follicular Lymphoma. *Leuk Lymphoma*. 2014 Mar 7. Epub ahead of print.
151. Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJ. Oral Alpha-lipoic Acid to Prevent Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. *Support Care Cancer*. 2014 May; 22(5): 1223-31. Epub 2013 Dec 22.
152. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A. Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity. (N08CB/Alliance). *J Clin Onc*. 2014 Apr 1;32(10): 997-1005. Epub 2013 Dec 2.
153. Garol EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yorasov S, Perol M. Ramucirumab plus Docetaxel Versus Placebo Plus Docetaxel for Second-Line Treatment of Stage IV Non-Small-Cell Lung Cancer after Disease Progression on Platinu-Based Therapy (REVEL): A Multicentre, Double Blind Randomized Phase 3 Trial. *Lancet*. 2014 Aug 23;384(9944):665-73. Epub 2014 Jun 2.

154. Alberts SR, Yu TM, Behrens RJ, Renfro LA, Srivastava G, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim GP, Mazurczak MA, Hornberger J. Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer. *Pharmacoeconomics*. 2014 Aug 26. (Epub ahead of print).
155. Moore HC, Unger JM, Phillips K, Boyle F, Hitre E, Porter D, Francis P, Goldstein L, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens, Jr. FL, Gelber RD, Hortobagyl GN, Albain KS. Goserelin for Ovarian Protection during Breast Cancer Adjuvant Chemotherapy. *N Engl J Med*. 2015. 372:923-32.
156. Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. *Clin Colorectal Cancer*, 2015 Jun; 14(2):72-80. (Epub 2015 Jan 8).
157. Hershman DL, Unger JM, Crew KD, Awad D, Dakhil Sr, Gralow J, Greenlee H, Lew, DL, Minasian LM, Till C, Wade JL 3rd, Meyskens FL, Moinpour CM. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. *J Clin Onc*. 2015 Jun 10;33(17):1910-1917. (Epub 2015 May 4).
158. Spigel DR, McCleod M, Waterhouse D, Cobo M, Paz-Ares L, Inglesias L, Dakhil S, Novello S, Mekhail T, Stemmer SM, Filip E, Grossi F, Reck M, Garcia-Ribas I, Charpentier EJ, Kim ES, Hainsworth J, Burris HA, Lynch TJ, Socinski MA, Shepherd FA. Phase III Study of Gemcitabine/Carboplatin With or Without Iniparib in Patients with Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC). *J Clin Onc*. 2015 (suppl; abstr TPS220).
159. Reddy, PS, Rahal AK, Kallail KJ, Moore, Jr DF, Truong PV, Mattar BI, Cannon MW, Nabbout NH, Page SJ, Truong QV, Dakhil C, Deutsch JM, Dakhil SR. The Application of Next-Generation Sequencing in the Community Clinical Oncology Setting. Abstract #166875, submitted at ASCO Annual Meeting, June 3-7, 2016, Chicago, IL.
160. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A. Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-Induced Sensory Neurotoxicity, N08CB (Alliance). *J Clin Oncol*. 2014 Apr 1;32(10):997-1005. (Epub 2013 Dec 2).
161. Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F: REVEAL-1, A Phase 2 Dose Regimen Optimization Study of Vosaroxin in Older Poor-Risk Patients with Previously Untreated Acute Myeloid Leukemia. *Br J Haematol*. 2015 Mar;168(6):796-805. Epub 2014 Nov 17.
162. Park H, Qin R, Smith TJ, Atherton PJ, Barton DL, Sturtz K, Dakhil SR, Anderson DM, Flynn K, Puttabasavaiah S, Le-Lindqwister NA, Padula GD, Loprinzi CL: North Central Cancer Treatment Group N10C2 (Alliance): a Double-Blind Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes. *Menopause*. 2015 Jun;22(6):627-632.
163. Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang P, Sparano JA, Head B, Goldstein L, Haley B, Dakhil S, Reid JE, Hartman A, Manola J, Ford JM. A Phase II Study of Gemcitabine, Carboplatin and Iniparib as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer with Assessment of a Tumor-Based Measure of Genomic Instability (PrECOG 0105). *J Clin Oncol*. 2015 Jun 10;33(17):1895-1901. Epub 2015 Apr 6.
164. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Balint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA, SQUIRE Investigators: Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin Alone as First-Line Therapy in Patients with Stage IV Squamous Non-Small-Cell Lung Cancer (SQUIRE): an Open-Label, Randomised, Controlled Phase 3 Trial. *Lancet Oncol*. 2015 Jul;16(7):763-764. Epub 2015 Jun 1.
165. Wagner-Johnson ND, Sloan JA, Liu H, Karnes AE, Hines SL, Puttabasavaiah S, Dakhil SR, Lafky JM, Perez EA, Loprinzi CL: 5-Year Follow-up of a Randomized Controlled Trial of Immediate Versus Delayed Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole After Tamoxifen: N03CC (Alliance) Trial. *Cancer*. 2015 Aug 1;121(15):2637-2543. Epub 2015 Apr 30.

166. Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL. Clinical Course of Oxaliplatin-Induced Neuropathy: Results from the Randomized Phase III Trial N08CB (Alliance). *J Clin Oncol*, 2015 Oct 20;33(30):3416-3422. Epub 2015 Aug 17.
167. Schnadig ID, Agajanian R, Dakhil SR, Gabrail NY, Smith RE, Taylor CW, Wilks S, Cooper W, Mosier M, Payne Y, Klepper M, Vacirca JL: Phase III study of APF530 Versus Ondansetron with a Neurokinin 1 Antagonist + Corticosteroid in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: MAGIC Trial. *J Clin Oncol*. 2015;33 (suppl 28S, abstr 68).
168. Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, Mattar BI, Moore DF Jr, Nikcevich D, Loprinzi CL. A Randomized Comparison of Once Weekly Epoetin Alfa to Extended Schedule Epoetin or Darbepoetin in Chemotherapy-Associated Anemia. *Am J Hematol*, 2015 Oct;90(10):877-881. Epub 2015 Aug 14.
169. Sartor AO, Cooperberg MR, Armstrong AJ, Vogelzang NJ, Vacirca JL, Scholz MC, Dakhil SR, Nordquist LT, Heath EI, Chang NN, Lill JS, Higano CS: Real-World Experience of Therapeutic Sequencing and Time to First Anticancer Intervention (ACI) Following Sipuleucel-T (sip-T): Initial Data from the PROCEED Registry. *J Clin Oncol*. 34, 2016 (suppl 2S, abstr 194).
170. Reddy PS, Rahal AK, Kallail KJ, Moore DF, Truong PV, Mattar BI, Cannon MW, Nabbout NH, Page SJ, Truong QV, Dakhil C, Deutsch JM, Dakhil SR: The Application of Next-Generation Sequencing in the Community Clinical Oncology Setting. *J Clin Oncol*. 34, 2016 (suppl; abstr e23145)
171. Geller RB, McLaughlin T, McLeod K, Bajaj M, Dakhil SR, Braun E, Chu DT, Gabrail NY, Marks SM, Schwartzberg LS: Real-world Effectiveness of Palonosetron Within a Three-Drug Regimen to Prevent Chemotherapy Induced Nausea and Vomiting (CINV) Following Highly Emetogenic Chemotherapy (HEC). *J Clin Oncol*. 34, 2016 (suppl; abstr e18231)
172. Hortobagyl GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband, Masuda N, Dakhil SR, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baseiga J: Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results from BOLERO-2. *J Clin Oncol*. 2016 Feb 10;34(5):419-426. Epub 2015 Oct 26.
173. Conley CC, Kamen CS, Heckler CE, Janelsins MC, Morrow GR, Peppone LJ, Scalzo AJ, Gross H, Dakhil S, Mustian KM, Palesh OG: Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy. *J Clin Psychopharmacol*. 2016 Feb;36(1):82-85.
174. Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, Lafky JM, Qin R, Grothey A, Loprinzi CL. MC11C4: A Pilot Randomized, Placebo-Controlled, Double-Blind Study of Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy. *Support Care Cancer*. 2016 Mar;24(3):1071-1078. Epub 2015 Aug 8.
175. Majithia N, Atherton PJ, Lafky JM, Wagner-Johnston N, Olson J, Dakhil SR, Perez EA, Loprinzi CL, Hines SL: Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women with Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy: a 5-Year Follow-Up. *Support Care Cancer*. 2016 Mar;24(3):1219-1226. Epub 2015 Aug 23.
176. Peoples AR, Bushunow PW, Garland SN, Heckler CE, Roscoe JA, Peppone LL, Dudgeon DJ, Kirshner JJ, Banerjee TK, Hopkins JO, Dakhil SR, Flannery MA, Morrow GR. Buspirone for Management of Dyspnea in Cancer Patients Receiving Chemotherapy: a Randomized Placebo-Controlled URCC CCOP Study. *Support Care Cancer*, 2016 Mar;24(3): 1339-1347. Epub 2015 Sep. 2.
177. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2016 Mar 20;34(9):953-962. Epub 2016 Jan 25.
178. Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyl GN, Meht RS, Rae JM: Fulvestrant Decreases Anastrozole Drug Concentrations when Taken Concurrently by Patients with Metastatic Breast Cancer Treated on SWOG Study S0226. *Br J Clin Pharmacol*. 2016 Jun;81(6):1134-1141. Epub Apr 8.

179. Perol M, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Kowalyszyn RD, Pikiel J, Lewanski CR, Thomas M, Dakhil S, Kim JH, Karaseva N, Yurasov S, Zimmermann A, Lee P, Carter GC, Reck M, Cappuzzo F, Garon EB. Quality of Life Results from the Phase 3 REVEL Randomized Clinical Trial of Ramucirumab-Plus-Docetaxel Versus Placebo-Plus-Docetaxel in Advanced/Metastatic Non-Small Cell Lung Cancer Patients with Progression after Platinum-Based Chemotherapy. *Lung Cancer.* 2016 Mar;93:95-103. Epub 2016 Jan 19.
180. Jatoi A, Qin R, Satele D, Dakhil S, Kumar P, Johnson DB, Thomas SP, Stella PJ, Castillo J, Li M, Fernandez-Zapico M: “Enjoy Glass of Wine Before Eating.” A Randomized Trial to Test the Orexigenic Effects of this Advice in Advanced Cancer Patients. *Support Care Cancer.* 2016 Apr 2. Epub ahead of print.
181. Belada D, Georgiev P, Dakhil S, Inhorn LF, Andorsky D, Beck JT, Quick D, Pettengell R, Daly R, Dean JP, Pavlyuk M, Failloux N, Hubel K: Pixantrone-Rituximab Versus Gemcitabine-Rituximab in Relapsed/Refractory Aggressive non-Hodgkin Lymphoma. *Future Oncol.* 2016 Apr 20. Epub ahead of print.
182. Hulin C, Belch A, Shustik C, Petrucci MT, Duhrsen U, Lu J, Song K, Rodon P, Pegourie B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houch V, Chen G, Ervin-Haynes A Dimopoulos MA, Facon T. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized Phase III FIRST Trial. *J Clin Oncol.* 2016 Jun 20. Epub ahead of print.
183. Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O’Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S. PARTNER: An Open-Label, Randomized, Phase 2 Study of Docetaxel/Cisplatin Chemotherapy With or Without Panitumumab as First-Line Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. *Oral Oncol.* 2016 Oct;61:31-40. Epub 2016 Aug 20.
184. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ. Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. *J Clin Oncol* 2016 Nov 14. Epub ahead of Print.
185. Hortobagyl GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanian R, Zheng M, Lipton A. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women with Breast Cancer Metastatic to Bone. *JAMA Oncol.* Published online January 26, 2017.
186. Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GL, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM. Phase III Randomized Study of 4 Weeks of High-Dose Interferon- α -2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-AN1a-2a(microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). *J Clin Oncol.* Published online February 6, 2017.
187. Pili R, Jegede O, Carducci MA, Manola J, Groteluschen DL, Appleman LLO, Liu G, Shanks JC, Dakhil SR, Dutcher J, DiPaola RS. A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). *Clin Genitourin Cancer.* 2017 Apr 26. Pii: S1558-7673(17)30107-6. Epub ahead of print.
188. Choueiri, Toni K., et al. “Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.” *J Clin Onc*, vol. 35, no. 6, 2017, pp. 591–597., doi:10.1200/jco.2016.70.7398.
189. Shadman, M., Li, H., Rimsza, L., Leonard, J. P., Kaminski, M. S., Braziel, R. M., Spier, C. M., Gopal, A. K., Maloney, D. G., Cheson, B., Dakhil, S., LeBlanc, M., Smith, S. M., Fisher, R. I., Friedberg, J. W., & Press, O. (2016). Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016. *J Clin Onc*, 2017 Dec;128(22), 616.
190. Reck, Martin, et al. “Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.” *Lung Cancer Journal*, vol. 112, doi:10.1016/lungcan.2017.07.038.

191. Persky, Daniel O et al. “A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.” *American journal of hematology* vol. 93,4 (2018): 486-493. doi:10.1002/ajh.25010
192. Hamstra DA, Lee KC, Eisbruch A, et al. Double-blind placebo-controlled multicenter phase II trial to evaluate D-methionine in preventing/reducing oral mucositis induced by radiation and chemotherapy for head and neck cancer. *Head Neck.* 2018;40(7):1375-1388. doi:10.1002/hed.25115
193. Parker N, Dakhil C, Dakhil S. “Benign metastasizing leiomyoma – A contradiction in nomenclature.” *American College of Physicians, Internal Medicine Meeting*, April 2018
194. Young, Derek, et al. “A Retrospective Analysis Comparing Efficacy of Filgastrim-sndz Versus Filgastrim for Autologous, Peripheral Stem Cell Mobilization in Patients With Multiple Myeloma and Lymphoma.” *ASCO Annual Mtg.* 1-5 May 2018
195. Pérol, M., Ciuleanu, T. E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., ... Garon, E. B. (2016). “Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.” *Lung Cancer*, 93, 95-103. DOI: 10.1016/j.lungcan.2016.01.007
196. Nathaniel A. Parker, B.S., MS-4, Christopher S.R. Dakhil, MD, Shaker R. Dakhil, MD, Daniel Lalich, MD. “Metastasis of Benign Leiomyomas Outside the Uterus.” *Kansas Journal of Medicine*, vol. 11, iss. 2, May 2018.
197. Nathaniel A P DO, Christopher SR D MD, Shaker R D MD, Daniel L MD. Benign Metastasizing Leiomyoma and Intravenous Leiomyomatosis Following Total Hysterectomy: Two Case Reports and a Literature Review. *Open Acc J Oncol Med* 2(3)- 2018. OAJOM. MS.ID.000137
198. Janelins, Michelle c., et al. “Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study” DOI: 10.1200/JCO.2018.78.6624 *Journal of Clinical Oncology* - published online before print September 21, 2018.
199. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]. *Eur J Cancer.* 2018 Nov;103:287. doi: 10.1016/j.ejca.2018.09.022. Epub 2018 Sep 27. PubMed PMID: 30270112; PubMed Central PMCID: PMC6299293.
200. Sio TT, Atherton PJ, Pederson LD, Zhen WK, Mutter RW, Garces YI, Ma DJ, Leenstra JL, Rwigema JM, Dakhil S, Bearden JD, van der Veen SJ, Ganti AK, Schild SE, Miller RC. Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. *Int J Radiat Oncol Biol Phys.* 2019 Mar 1;103(3):686-696. doi: 10.1016/j.ijrobp.2018.10.035. Epub 2018 Nov 2. PubMed PMID: 30395904; PubMed Central PMCID: PMC6431240.
201. Choueiri, Toni K., et al. “Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update” DOI: 10.1016 *European Journal of Cancer*, Volume 94 , 115 – 125, 2018.02.012
202. Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, Dakhil SR, Minasian LM, Wade JL 3rd, Fisch MJ, Henry NL, Hershman DL. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). *Breast Cancer Res Treat.* 2018 Dec;172(3):603-610. doi:10.1007/s10549-018-4946-0. Epub 2018 Aug 29. PubMed PMID: 30159789.
203. Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2019

- Jan;20(1):88-99. doi: 10.1016/S1470-2045(18)30621-1. Epub 2018 Nov 30. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10. PubMed PMID: 30509771.
204. Kumar GK, Abidullah M, Elbadawi L, Dakhil S, Mawardi H. Epidemiological profile and clinical characteristics of oral potentially malignant disorders and oral squamous cell carcinoma: A pilot study in Bidar and Gulbarga Districts, Karnataka, India. J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):90-96. doi: 10.4103/jomfp.JOMFP_116_18. PubMed PMID: 31110423; PubMed Central PMCID: PMC6503790.
205. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. J Natl Cancer Inst. 2019 Feb 1;111(2):210-213. doi: 10.1093/jnci/djy185. PubMed PMID: 30371800.
206. Mehta, Rita S., et al. “Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer” DOI: 10.1056/NEJMoal1811714. *The New England Journal of Medicine.* March 28, 2019.
207. Jesus G. Berdeja, Michael C. Heinrich, Shaker R. Dakhil, Stuart L. Goldberg, Martha Wadleigh, Philip Kuriakose, Jorge Cortes, Jerald Radich, Bret Helton, David Rizzieri, Carole Paley, Ilva Dautaj & Michael J. Mauro (2019) “Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis” *Leukemia & Lymphoma*, DOI: 10.1080/10428194.2019.1590569. March 26, 2019.
208. T.K. Owonikoko, et al. “LBA1_PR - Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study” *Annals of Oncology*, Volume 30, 20019 Supplement 2. doi:10.1093/annonc/mdz072. April 11, 2019.
209. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Linden HH, Livingston RB, Hortobagyi GN. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. N Engl J Med. 2019 Mar 28;380(13):1226-1234. doi: 10.1056/NEJMoal1811714. Erratum in: N Engl J Med. 2019 Jun 6;380(23):2282. PubMed PMID: 30917258.
210. LoPiccolo J, Schollenberger MD, Dakhil S, Rosner S, Ali O, Sharfman WH, Silk AW, Bhatia S, Lipson EJ. “Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.” J Immunother Cancer. 2019 Jul 8;7(1):170. doi: 10.1186/s40425-019-0661-6.
211. Persky, Daniel O et al. “A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.” *American journal of hematology* vol. 93,4 (2018): 486-493. doi:10.1002/ajh.25010
212. George, Daniel J. et al. “Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial”. *The Oncologist.* 2019 Aug 9. doi: 10.1634/theoncologist.2019-0316
213. Jesus G. Berdeja, Michael C. Heinrich, Shaker R. Dakhil, Stuart L. Goldberg, Martha Wadleigh, Philip Kuriakose, Jorge Cortes, Jerald Radich, Bret Helton, David Rizzieri, Carole Paley, Ilva Dautaj & Michael J. Mauro (2019) Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. *Leukemia & Lymphoma*, 60:10, 2384-2393, DOI: 10.1080/10428194.2019.1590569
214. Julie R Gralow, William E Barlow, Alexander H G Paterson, Jieling L Miao, Danika L Lew, Alison T Stopeck, Daniel F Hayes, Dawn L Hershman, Mark M Schubert, Mark Clemons, Catherine H Van Poznak, Elizabeth C Dees, James N Ingle, Carla I Falkson, Anthony D Elias, Michael J Messino, Jeffrey H Margolis, Shaker R Dakhil, Helen K Chew, Kim Z Dammann, Jeffrey S Abrams, Robert B Livingston, Gabriel N Hortobagyi, Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307, JNCI: Journal of the National Cancer Institute, , djz215, doi:10.1093/jnci/djz215

215. Mehta, Rita S et al. "Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer." *The New England journal of medicine* vol. 380,13 (2019): 1226-1234. doi:10.1056/NEJMoa1811714
216. Daniel J. George, Colin Hessel, Susan Halabi, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Joel Picus, Eric J. Small, Shaker Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Michael J. Morris, Toni K. Choueiri. "Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. *Oncologist.*" 2019 Nov; 24(11): 1497–1501. Published online 2019 Aug 9. Doi:10.1634/theoncologist. 2019-0316
217. Hershman DL, Unger JM, Hillyer GC, Moseley A, Arnold KB, Dakhil SR, Esparaz BT, Kuan MC, Graham ML 2nd, Lackowski DM, Edenfield WJ, Dayao ZR, Henry NL, Gralow JR, Ramsey SD, Neugut AI. "Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer": SWOG S1105. *J Clin Oncol.* 2020 May 5:JCO1902699. doi: 10.1200/JCO.19.02699
218. Williams W., Dakhil S., Calfa C., Holmes J., Bhattacharya S., Lukas J., Tan-Chiu E., Peoples G., Sunkari V., Lacher M., Wiseman C. Abstract #97: "Breast Cancer Grade and Clinical Benefit in Patients with Advanced Breast Cancer Treated with an Engineered Whole Tumor Cell-Targeted Immunotherapy Alone or in Combination with Checkpoint Inhibition." (Submitted to ASCO 05/20/2020)
219. Khalil Choucair, Bassam Ibrahim Mattar, Quoc Van Truong, Travis Koeneke, Phu Van Truong, Christopher Dakhil, Michael W Cannon, Seth Joel Page, Jeremy Michael Deutsch, Eric Carlson, Dennis Frederic Moore, Nassim H Nabbout, K James Kallail, Shaker R Dakhil, Pavan S Reddy. "Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice." *Journal of Clinical Oncology*, Advance online publication. May 20, 2020. Doi:10.1200/JCO.2020.38.15 No. 15, supplemental 352.7. Published online May 25, 2020.
220. Watson DD, Farha NM, Kallail KJ, Dakhil S, Farha AJ. "From Radical to Partial Nephrectomy in the Setting of Solitary Functioning Kidney: Neoadjuvant Treatment of Renal Cell Carcinoma." *Rev Urol.* 2020;22(3):126-129. PMID: 33239972; PMCID: PMC7672501.
221. Waqar, Saiama N et al. "A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)." *Clinical lung cancer*, S1525-7304(20)30293-X. 14 Oct. 2020, doi:10.1016/j.clcc.2020.09.013
222. Van Poznak CH, Unger JM, Darke AK, Moinpour C, Bagramian RA, Schubert MM, Hansen LK, Floyd JD, Dakhil SR, Lew DL, Wade JL 3rd, Fisch MJ, Henry NL, Hershman DL, Gralow J. "Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. *JAMA Oncol.* 2020 Dec 17:e206353. doi: 10.1001/jamaoncol.2020.6353. Epub ahead of print. PMID: 33331905; PMCID: PMC7747039.
223. Ailawadhi S, Sexton R, Lentzsch S, et al. "Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. *Clin Cancer Res.* 2020;26(15):3969-3978. doi:10.1158/1078-0432.CCR-19-1997.
224. Taofeek K. Owonikoko, et al. "Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451". *Journal of Clinical Oncology.* Epub 2021 March 08. Doi: 10.1200/JCO.20.02212. PMID: 33683919.
225. Algazi, Alain P et al. "Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial." *Nature Medicine* vol. 26,10 (2020): 1564-1568. doi:10.1038/s41591-020-1060-8.
226. O'Shaughnessy, Joyce et al. "Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study." *European journal of cancer (Oxford, England : 1990)* vol. 152 (2021): 223-232. doi:10.1016/j.ejca.2021.03.047

227. Barton, Debra L et al. "[A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 \(Alliance\).](#)" *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* vol. 28,12 (2020): 6085-6094. doi:10.1007/s00520-020-05461-6
228. Halfdanarson, Thorvardur et al. "[N064A \(Alliance\): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma.](#)" *The Oncologist*. 2021 October.
229. Khalil Choucair, Bassam Ibrahim Mattar, Quoc Van Truong, Travis Koeneke, Phu Van Truong, Christopher Dakhil, Michael W Cannon, Seth Joel Page, Jeremy Michael Deutsch, Eric Carlson, Dennis Frederic Moore, Nassim H Nabbout, K James Kallail, Shaker R Dakhil, Pavan S Reddy. [Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice.](#) *The Oncologist*, Feb 19, 2022.
230. Herbst, Roy S et al. "[COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.](#)" *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, JCO2200227. 22 Apr. 2022, doi:10.1200/JCO.22.00227
231. Lipsyc-Sharf, Marla et al. "[Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.](#)" *The oncologist* vol. 27,4 (2022): 292-298. doi:10.1093/oncolo/oyab025
232. McLouth LE, Zheng Y, Smith S, et al. [Patient-reported tolerability of adjuvant ipilimumab \(3 or 10 mg/kg\) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609 \[published online ahead of print, 2022 Aug 27\].](#) *Qual Life Res*. 2022;10.1007/s11136-022-03226-8. doi:10.1007/s11136-022-03226-8
233. Martin M, Hegg R, Kim SB, et al. [Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.](#) *JAMA Oncol*. 2022;8(8):1190-1194. doi:10.1001/jamaoncol.2022.1488
234. Choucair K, Page SJ, Mattar BI, et al. [Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience \[published online ahead of print, 2022 Nov 23\].](#) *Clin Breast Cancer*. 2022;S1526-8209(22)00261-0. doi:10.1016/j.clbc.2022.11.005
235. McLouth, Laurie E et al. "Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609." *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation* vol. 32,1 (2023): 183-196. doi:10.1007/s11136-022-03226-8

Publications: (not peer reviewed)

1. Marymont JV, Dakhil SR, Brake D: Malpositioned hepatic artery catheters [letter]. *J Clin Onc*. 1986 Mar: 4(3):442.

Presentations to professional audiences:

1. Dakhil S, Ensminger W, Kindt G: "Maintenance Of Constant CSF MTX Levels with a Totally Implanted Infusion System." Presented to the American Association for Cancer Research (AACR) 1980:21:149.
2. Ensminger W, Dakhil S, Cho K: "Improved Regional Selectivity Of Hepatic Arterial BCNU Plus Degradable Starch Microspheres." Presented to the American Society for Clinical Oncology (ASCO) 1981:22:382.
3. Keller J, Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R: "Effective Prolonged Hepatic Arterial Chemotherapy Using a Totally Implanted Delivery System." Presented to the ASCO 1981:22:1788,C87.

4. Dakhil S, Ensminger W, Strother V, Kindt G, Chandler W, Greenberg H: "Pharmacokinetics Of Intraventricular 5-Fluoro-2'deoxyuridine (FUDR) In Patients with Meningeal Neoplasia." Presented to the AACR 1981:22:178,C706.
5. Ensminger W, Dakhil S, Doan K, Cho K: "Clinical pharmacology of dichloromethotrexate in hepatic arterial infusions." Presented to the AACR 1981:22:271,C1077.
6. Dakhil S, Hynes H, Kim P, Zatzkin J: "Wichita Community Experience with The Infusaid Pump For Chemotherapy Of Liver Malignancies." Presented to the American College of Physicians Kansas Regional Meeting, Kansas City, Missouri, February 1983.
7. Dakhil S, Hynes H, Zatzkin J: "Wichita Community Experience with The Implantable Catheter (Port-A-Cath)." Presented to the ASCO 1985:4:270,C1050.
8. "Surgical Management Of Carcinoma Of The Rectum," 11/24/94, St. Francis Regional Medical Center, Surgery Tumor Conference.
9. "Update on Lymphomas," 1/11/94, St. Francis Regional Medical Center, Medicine Conference.
10. "Oncology Case Conference," 12/21/93, HCA-Wesley Medical Center.
11. "Oncology Case Conference," 11/29/94, HCA-Wesley Medical Center.
12. "Precancerous Syndrome," 4/14/95, Family Medicine Spring Program, Cancer Update, University of Kansas School of Medicine - Wichita.
13. "Tamoxifen Prevention Program, STAR Program: Western Plains Regional Medical Center," Tumor Board, Dodge City, KS. 6/17/99.
14. "Phase II Trial Of a Weekly Taxol (T), 5-Fluorouracil (FU) And Leucovorin (LV) Regimen In Patients with Metastatic Breast Cancer: An Update," presented to the National Arab American Medical Association, Lebanon, 7/03/99.
15. "Small Cell Lung Cancer," 10/06/99, ONS Stars Over the Garden Botanica Gardens, Wichita, KS.
16. "Breast Cancer Prevention," 10/28/99, CCOP, Wichita, KS.
17. "Relationship Between Smoking and Prognostic Factors and Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Sipuleucel-T: Preliminary analysis of the PROCEED registry," Abstract #216, Poster Board # H18, presenting to ASCO GU 2017, Poster Session A, on 2/16/17.
18. "CheckMate 568: A phase 2/3 Trial of Nivolumab Plus Ipilimumab Combination Therapy as First-Line Treatment for Stage IV NSCLC." Abstract #568. Presented at ASCO 2017, June 3, 2017.
19. "Quality of Life (QoL) in Elderly NSCLC Patients Treated with nab-Paclitaxel/Carboplatin (*nab-PC*) in the ABOUND 70+ Trial." Poster presentation at ESMO 2017 Congress, September 9, 2017, Madrid Spain.
20. "Antigen (Ag) spread after sipuleucel-T and correlation with overall survival (OS): A real-world experience." Abstract #16504. Published in conjunction with 2019 ASCO Annual Meeting. J Clin Oncol 37, 2019.
21. Hershman, D. et. al. "Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105." Abstract #6516. Presented at 2019 ASCO Annual Meeting. J Clin Oncol 37, 2019.
22. Williams, W. et. al. "Safety and efficacy of a phase I/IIa trial (NCT03066947) of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer." Abstract #14026. Published in conjunction with 2019 ASCO Annual Meeting. J Clin Oncol 37, 2019.
23. Van Poznak, C. et. al. "Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211." Abstract #11502. Presented at 2019 ASCO Annual Meeting. J Clin Oncol 37, 2019.
24. Choucair, K. et al. "Liquid biopsy: a promising gateway to implementing precision medicine and clinical trials; a community-based oncology practice experience." Presented at 2020 ASCO Annual Meeting.

25. Bandos, Hanna et al. "Assesment of Estrogen Receptor (ESR1) mRNA Expression for Prediction of Extended Aromatase Inhibitor Benefit in HR–positive Breast Cancer Using NRG Oncology/NSABP B-42." Spotlight Poser-Discussion Session at *SABCS*.
26. Choucair, K. et al. "Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice." Presented at 2021 ASCO Annual Meeting.

Presentations to lay audiences:

1. "Emotional Components," 10/10/91, Victory in the Valley, Wichita, KS.
2. "What Every Doctor Wished Their Patients Knew About Cancer," 10/24/91, Victory in the Valley, Wichita, KS.
3. "Death with Dignity," 2/16/92, Newton Church.
4. "General Oncology," 2/19/92, Wichita State University Physical Therapy Students.
5. "Lebanon," 2/26/92, Collegiate High School International Day.
6. "General Oncology," 3/12/92, Ascension Lutheran Church, Wichita, KS.
7. "General Oncology," 5/28/92, Victory in the Valley, Wichita, KS.
8. "Surgical Management of Carcinoma of the Rectum," 11/24/93, St. Francis Regional Medical Center Surgery Tumor Conference.
9. "Oncology Case Conference," 12/21/93, Columbia Wesley Medical Center.
10. "Update on Lymphomas," 1/11/94, St. Francis Regional Medical Center Internal Medicine Rounds.
11. "Oncology Case Conference," 11/29/94, Columbia Wesley Medical Center.
12. "Precancerous Syndrome," 4/14/95, Family Medicine Spring Program, Cancer Update, UKSM-W.
13. "Breast Cancer: What You Should Know, What We Can Do," 3/10/00, Via Christi Cancer Center audio tape. Wichita, KS.
14. "Breast Cancer Awareness," 10/3/00, Junior League of Wichita, Inc.
15. "I Can Cope." Presentation to Memorial Hospital in McPherson 10/03/02.
16. "Breast Cancer Awareness," 11/07/02, Victory In the Valley Support Group.

Updated: 3/6/2023